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PART 1
Reducing harm, supporting recovery: a health-led 
approach to drug and alcohol use in Ireland 2017— 
20251 was launched on 17 July 2017 by An Taoiseach 
Leo Varadkar, alongside the Minister for Health Simon 
Harris TD, and the Minister for Health Promotion and the 
National Drugs Strategy, Catherine Byrne TD. 
A health-led approach
The strategy follows through on the commitment made by Government in 
May 2016 ‘to pursue a health-led rather than a criminal justice approach 
to drug use’.2 At the launch of the strategy, all of the speakers emphasised 
the importance of this shift in approach.3,4,5 The Taoiseach said that 
‘treating substance abuse and drug addiction as a public health issue, 
rather than a criminal justice issue, helps individuals, helps families, 
and helps communities. It reduces crime because it rebuilds lives’.3 
Compassion has been identified internationally as an ‘essential ingredient’6 
of a health-led approach to drug policy and is a recurring theme both in 
the strategy document and in what was said at the launch. In her speech, 
Minister Byrne said ‘there is one word that runs like a thread throughout 
the strategy, and that word is “compassion” — compassion is the basis for a 
health-led approach to addiction’.4
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In brief
The Government launched Ireland’s third 
national drugs strategy in July. While there 
are a number of consistent themes linking all 
three strategies, the shift towards a health-
led approach, already apparent in previous 
strategies, is explicitly made in Reducing harm, 
supporting recovery: a health-led response to 
drug and alcohol use in Ireland 2017—2025. 
The values that the new strategy espouses, and particular actions 
that give these values expression in very concrete ways, moves 
Ireland towards the more progressive end of the spectrum 
internationally.1 Another important development in terms of 
international comparisons is the description of Reducing harm, 
supporting recovery as the first integrated drug and alcohol 
strategy in Ireland. Policy coherence is an indicator used for 
international comparison and the new strategy would be seen in a 
different light from previous strategies in this context.2
These changes, in particular the willingness to examine the 
legislation relating to the criminal status of certain possession 
offences, reflect developments and debate in drug policy 
internationally. While human rights is only mentioned specifically 
once in the strategy document, the overall vision of the strategy, 
the values underpinning it and some specific actions would 
suggest that there is greater emphasis on human rights than in 
previous strategies. 
The strategy’s humanist values promote inclusion, fairness and 
participation, and also the use of evidence in policy development 
and implementation. The growth in the knowledge base since 
the beginning of the last strategy, and the increasing emphasis 
on evidence-informed decision-making internationally, makes 
an increasing and more consisent use of evidence more likely. 
Evidence-informed policy also implies that success will be 
measured by appropriate indicators. A recent EMCDDA report 
stated that ‘evaluation is essential for effective policymaking, 
helping ensure that policies and programmes have the desired 
effect, provide value for money and do not have negative 
unintended consequences’.3 The stategy will use a number of 
key performance indicators, each of which will be supported 
by information systems providing the data, to give an accurate 
determination of performance.
It is probably in this respect that the Reducing harm, supporting 
recovery is most innovative. The performance measurement 
system developed to assess the response to problem substance 
use at a population level is both an evaluation instrument and a 
mechanism to enable funding to be allocated on a more equitable 
and rational basis. The successful implementation of this system 
during the lifetime of this strategy will be the clearest expression 
of its commitment to fairness, efficient use of resources and the 
use of evidence. 
1   Pike B (2015) How does Ireland’s drugs policy compare with others? 
Drugnet Ireland, 53: 4-5. http://www.drugsandalcohol.ie/23687/
2   Pompidou Group (2012) Policy paper providing guidance to policy makers 
for developing coherent policies for licit and illicit drugs. Strasbourg: 
Council of Europe. http://www.drugsandalcohol.ie/17318/
3   European Monitoring Centre for Drugs and Drug Addiction (2017) 
Evaluating drug policy: a seven-step guide to support the commissioning 
and managing of evaluations. Luxembourg: Publications Office of the 
European Union. http://www.drugsandalcohol.ie/27536/
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5 Harris S (2017) Speech by Simon Harris TD, Minister for Health at 
the launch of Reducing harm, supporting recovery: a health-led 
response to drug and alcohol use in Ireland 2017—2025.  
http://www.drugsandalcohol.ie/27611/ 
6 Pike B (2016) What’s in a drugs strategy? Drugnet Ireland,  
57: 10—11. http://www.drugsandalcohol.ie/25490/ 
7 Department of Community, Rural and Gaeltacht Affairs (2009) 
National drugs strategy (interim) 2009—2016. Dublin: Department of 
Community, Rural and Gaeltacht Affairs.  
http://www.drugsandalcohol.ie/12388/ 
8 Griffiths P, Strang J and Singleton N (2016) Rapid expert review of the 
national drugs strategy 2009—2016. Dublin: Department of Health. 
http://www.drugsandalcohol.ie/27289/ 
9 Department of Health (2012) Steering group report on a national 
substance misuse strategy. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/16908/ 
 
PART 2
Structure of the new drugs strategy
The new strategy1 indicates a departure from the pillar 
structure of the two previous drug strategies.2 It is 
underpinned by a set of core values and is structured around 
a vision and five goals — each goal has a set of objectives, 
accompanying actions and performance indicators. While the 
structure has changed, its overall direction is very similar to 
previous strategies.  
Vision and values of the new drugs strategy
 
Vision
The strategy’s vision is for:  
A healthier and safer Ireland, where public health 
and safety is protected and the harms caused to 
individual, families and communities by substance 
misuse are reduced and every person affected by 
substance use is empowered to improve their health 
and wellbeing and quality of life. 
 
Values
To deliver on this vision, the strategy is underpinned by  
six values:  
• Compassion: A humane, compassionate approach 
focused on harm reduction which recognises that 
substance misuse is a healthcare issue. 
• Respect: Respect for the right of each individual to 
receive person-centred care based on his or her 
specific needs and to be involved in the development 
of their care plan. 
• Equity: A commitment to ensuring that people 
have access to high-quality services and support, 
regardless of where they live or who they are. 
• Inclusion: Diversity is valued, the needs of particular 
groups are accommodated and wide-ranging 
participation is promoted. 
• Partnership: Support for maintaining a partnership 
approach between statutory, community and 
voluntary bodies and wider society to address drug 
and alcohol issues. 
• Evidence-informed: Support for the use of high-
quality evidence to inform effective policies and 
actions to address drug and alcohol problems (p. 16).
Integrated drug and alcohol strategy
Reducing harm, supporting recovery is the first ‘integrated’ 
drug and alcohol strategy in Ireland. In his foreword to the 
strategy, the Taoiseach notes that ‘many Irish people engage 
in harmful drinking patterns and alcohol has become a major 
drugs issue’ (p. 3). While a Government commitment was 
made in 2009 to produce ‘a combined National Substance 
Misuse Strategy to cover both alcohol and drugs’ (p. 5),7 
this did not happen. The new strategy takes account of 
what the Expert Review Group for the 2009—2016 strategy 
described as this ‘elephant in the room’ (p. 4)8 for Irish drug 
policy, i.e. alcohol. The strategy defines substance misuse as 
‘the harmful or hazardous use of psychoactive substances, 
including alcohol, illegal drugs and the abuse of prescription 
medicines’ (p. 7).1 There is an explicit commitment to ensuring 
‘an integrated public health approach to drugs and alcohol is 
delivered as a key priority’ (p. 22). The strategy complements 
the Public Health (Alcohol) Bill and reinforces some of the key 
elements of the alcohol-focused National Substance Misuse 
Strategy from 2012.9 However, illicit drug use continues to be 
the primary focus of many of the actions of the new strategy 
from 2017 to 2020. It is not clear from the strategy and its 
accompanying action plan how the challenges of implementing 
such an integrated approach will be overcome.  
Additional funding for 2017
At the launch, Minister for Health Simon Harris TD 
expressed the Government’s commitment to ‘making 
progress on the delivery of the actions in the strategy in 
the current year’.5 An additional €3 million was allocated 
to drug initiatives in Budget 2017 to: 
• Commission 105 new treatment episodes from 
residential and rehabilitation services.
• Implement a pilot supervised injecting facility in Dublin 
City centre (expected to be open by the end of 2017).
• Support the phased increase from Q3 2017 in the 
availability of buprenorphine/naloxone treatment as 
an alternative treatment for the identified cohorts 
of patients for whom methadone treatment is not 
suitable.
• Fill gaps in addiction service provision for under 
18-year-olds.
• Provide more detoxification places in community and 
residential settings in 2018.
Lucy Dillon
1 Department of Health (2017) Reducing harm, supporting recovery: a 
health-led response to drug and alcohol use in Ireland 2017—2025. 
Dublin: Department of Health. http://www.drugsandalcohol.ie/27603/
2 Government of Ireland (2016) Programme for partnership government. 
Dublin: Department of the Taoiseach. http://www.drugsandalcohol.
ie/25508/
3 Varadkar L (2017) Speech by An Taoiseach Mr Leo Varadkar TD  
to launch Reducing harm, supporting recovery: a health-led 
response to drug and alcohol use in Ireland 2017—2025.  
http://www.drugsandalcohol.ie/27650/ 
4 Byrne C (2017) Speech by Catherine Byrne TD, Minister of State for 
Health Promotion and the National Drugs Strategy at the launch of 
Reducing harm, supporting recovery: a health-led response to drug 
and alcohol use in Ireland 2017—2025. http://www.drugsandalcohol.
ie/27651/ 
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17 the participation of individuals, families and communities in 
responding to the drug situation. Below are brief descriptions 
of each goal, its objectives, and elements of the 50 
accompanying actions.
Goal 1: To promote and protect health and wellbeing 
This goal focuses on prevention. It aims to:
 
Protect the public from threats to health and 
wellbeing related to substance misuse by preventing 
early use of alcohol and other drugs among young 
people, influencing behaviour and challenging 
social norms and attitudes and providing targeted 
interventions aimed at minimising harm for those 
who have already started to use substances. (p. 17) 
There are three objectives to this goal: 
1.1 To promote healthier lifestyles within society 
Actions include:
• To ensure that the commitment to an integrated public 
health approach to drugs and alcohol is delivered as a key 
priority by developing a relevant initiative and promoting 
the use of evidence-based approaches to mobilising 
community action on alcohol (1.1.1).
• To improve the delivery of substance use education across 
all sectors (1.1.2).
 
1.2 To prevent use of drugs and alcohol at a young age 
Actions include:
• To support the Social, Personal and Health Education 
(SPHE) by promoting effective communications between 
schools and Drug and Alcohol Task Forces (1.2.3).
• To improve supports for young people at risk of early 
substance use by prioritising initiatives under the new DEIS 
[Delivering Equality of Opportunity in Schools] programme 
to address early school leaving; and providing a continuum 
of support for young people encountering difficulty in 
mainstream education (1.2.5).
• To facilitate increased use of school buildings, where 
feasible, for afterschool care and out-of-hours use to 
support local communities (1.2.7).
• To improve services for young people at risk of substance 
misuse in socially and economically disadvantaged 
communities by developing a new scheme to provide 
targeted, appropriate and effective services (1.2.8).
 
1.3 To develop harm reduction interventions targeting  
at risk groups
Actions include:
• To mitigate the risk and reduce the impact of parental 
substance misuse on babies and young children by 
developing protocols between addiction services, 
maternity services and children’s health and social care 
services (1.3.9c).
• To strengthen early harm reduction responses to 
current and emerging trends and patterns of drug use by 
establishing a working group to examine the evidence on 
responses such as drug testing and amnesty bins (1.3.11).
Goal 2: To minimise the harms caused by the use and misuse 
of substances and promote rehabilitation and recovery
This goal focuses on the range of treatment, rehabilitation 
and recovery services available to users. It recognises that 
‘timely access to appropriate services relevant to the needs 
and circumstances of the person concerned is of fundamental 
importance’ (p. 33). There are two objectives to the goal:
Action plan
The strategy covers an eight-year period (2017—2025), and 
is accompanied by a shorter-term action plan (2017—2020). 
The previous seven-year strategy had actions set out for 
its duration from the start. A review of that strategy found 
that the actions could not be reactive to change in the 
drug situation over time, which contributed to an overall 
perception of a decline in the strategy’s ‘relevance and 
momentum’ (p. 6)3 over its timeframe. At the launch of the 
strategy, the Taoiseach noted that having a new action plan 
from 2021 to 2025 ‘will ensure the continued relevance of 
the strategy until the end of its term’.4
Synergy with other strategies 
A noticeable feature of the new strategy and its action plan is 
a synergy with other Government strategies and policies. To 
minimise duplication, the waste of scarce resources and to 
maximise the impact of strategies, the Expert Review Group 
on the 2009—2016 national drugs strategy emphasised the 
importance of having clear ‘synergy and complementarity’3 
(p. 31) between the new strategy and other related strategies. 
These include broad strategies such as Healthy Ireland and the 
Action Plan for Education 2016—2020, as well those that target 
the needs of specific groups, such as the National Traveller 
and Roma Inclusion Strategy 2016—2020. The enactment of 
the Public Health (Alcohol) Bill would be critical to delivering 
on a number of the alcohol elements of the strategy. In her 
foreword to the document, Minister Catherine Byrne TD 
described the Bill as ‘a key step forward’ (p. 4), and in the 
main body of the document it is described as containing ‘the 
proposed legislative provisions to provide a public health 
response to issues associated with alcohol consumption in 
Ireland’ (p. 20). However, it is not mentioned in the action plan. 
Lucy Dillon
1 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
2 Department of Community, Rural and Gaeltacht Affairs  
(2009) National drugs strategy (interim) 2009—2016.  
Dublin: Department of Community, Rural and Gaeltacht Affairs. 
http://www.drugsandalcohol.ie/12388/ 
3 Griffiths P, Strang J and Singleton N (2016) Report of the rapid 
expert review of the national drugs strategy 2009—2016. Dublin: 
Department of Health. http://www.drugsandalcohol.ie/27289/ 
4 Varadkar L (2017) Speech by An Taoiseach Mr Leo Varadkar TD 
to launch Reducing harm, supporting recovery: a health-led 
response to drug and alcohol use in Ireland 2017—2025.  
http://www.drugsandalcohol.ie/27650/
 
PART 3
Goals of the drugs strategy
Five goals form the core of Reducing harm, supporting 
recovery: a health-led approach to drug and alcohol use 
in Ireland 2017—2025.1 Broadly speaking, they cover similar 
themes to those in the previous strategy’s pillars: prevention, 
treatment, rehabilitation, recovery, supply reduction, research 
and evidence. Goal 4 reflects an increased focus on supporting 
New National Drug and Alcohol 
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3.2 To implement effective law enforcement and supply 
reduction strategies and actions to prevent, disrupt or 
otherwise reduce the availability of illicit drugs 
Actions include:
• To support the role of law enforcement authorities in 
monitoring drug markets, in particular new drug markets, 
surface web and darknet drug markets (3.2.36).
• To consider the case for the use of Community Impact 
Statements within the criminal justice system in Ireland 
(3.2.37).
3.3 To develop effective monitoring and responses to  
evolving trends, public health threats and the emergence  
of new drug markets 
Actions include:
• To strengthen the response to the illegal drugs market 
by developing systems to monitor changing drug trends 
in line with the EU Early Warning System (3.3.38a); and to 
complete the development of the HSE public alert system 
for adverse events due to drugs (3.3.38b).
Goal 4: To support participation of individuals, families and 
communities 
This goal recognises the need to support communities by 
building on their capacity to respond to the drugs situation. 
It also emphasises the need for meaningful involvement of 
service users and their families in the planning, design and 
delivery of effective services. There are two objectives:
4.1 To strengthen the resilience of communities and build 
their capacity to respond
Actions include:
• To support and promote community participation in all 
local, regional and national structures (4.1.39).
• To measure the impact of drug-related crime and wider 
public nuisance issues on communities by piloting a 
Community Impact Assessment Tool (4.1.40).
• To strengthen the effectiveness of the Drug-Related 
Intimidation Reporting Programme (4.1.42).
4.2 To enable participation of both users of services and  
their families
Actions include:
• To build capacity within the problem substance use sector 
to develop a patient safety approach requiring services 
within a Quality Assurance Framework (4.2.43).
• To promote the involvement of service users and their 
families in decision-making structures and networks at all 
levels (4.2.44).
Goal 5: To develop sound and comprehensive evidence-
informed policies and actions
There are no objectives under this goal but its actions include:
• To strengthen Ireland’s drug monitoring system (5.1.45).
• To strengthen the National Drug Treatment Reporting 
System by requiring all publicly funded drug and alcohol 
services to complete the NDTRS (5.1.47).
• To improve knowledge of rehabilitation outcomes by 
undertaking a study on outcomes that takes into account 
the experiences of service users and their families (5.1.49).
Lucy Dillon
1 Department of Health (2017) Reducing harm, supporting  
recovery: a health-led response to drug and alcohol use  
in Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
2.1 To attain better health and social outcomes for people 
who experience harm from substance misuse and meet their 
recovery and rehabilitation needs 
This objective focuses on improving access to a range of 
services, for users generally and for some groups in particular. 
These include women, children and young people, groups with 
‘more complex needs’ (p. 44), and prisoners.  
Associated actions include:
• To strengthen the implementation of the National Drugs 
Rehabilitation Framework (2.1.12).
• To enhance the quality and safety of care in the delivery of 
opiate substitution therapy (OST) by implementing the HSE 
National Clinical Guidelines on OST (2.1.15).
• To further strengthen services to support families affected 
by substance misuse (2.1.17).
• To help individuals affected by substance misuse to build 
their recovery capital by monitoring and supporting the 
Framework for Community Employment Drug Rehabilitation 
Schemes (2.1.18a); and utilising the Social Inclusion and 
Community Activation Programme (SICAP) (2.1.18b).
• To increase the range of progression options for recovering 
drug users and develop a new programme of supported 
care and employment (2.1.19).
• To improve outcomes for people with comorbid 
severe mental illness and substance misuse problems 
by supporting the Mental Health Clinical Programme 
to address dual diagnosis (2.1.24a); and develop joint 
protocols between mental health services and drug and 
alcohol services (2.1.24b).
2.2 To reduce harm among high-risk users 
This objective focuses specifically on people who inject drugs 
and the issues of overdose and drug-related deaths. 
Among the associated actions are: 
• To provide enhanced clinical support to people who inject 
and mitigate the issue of public injecting by establishing a 
pilot supervised injecting facility (2.2.29).
• To continue to target a reduction in drug-related deaths 
and non-fatal overdoses by expanding the availability of 
naloxone to people who use drugs, their peers and family 
members (2.2.30b).
Goal 3: To address the harms of drug markets and reduce 
access to drugs for harmful use
This goal focuses on the range of activities that aim to reduce 
the supply of illicit drugs and deal with those involved in supply 
activities. It also considers the ways in which users are dealt 
with in the criminal justice system. There are three associated 
objectives:
3.1 To provide a comprehensive and responsive misuse of 
drugs control framework which ensures the proper control, 
management and regulation of the supply of drugs 
Associated actions are:
• To map the future direction and objectives of the Drug 
Treatment Court by carrying out an independent evaluation 
of it (3.1.34a).
• To consider the approaches taken in other jurisdictions to 
the possession of small quantities of drugs for personal use 
with a view to making recommendations on policy options 
to the relevant Minister within 12 months (3.1.35).
New National Drug and Alcohol 
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17 to sustain the active membership of those who are in a 
position to take action, and to ensure that community voices 
are heard at all levels. In her response to such concerns 
expressed at the launch of the new strategy, Minister Byrne 
gave assurances that the structures would deliver on this for 
the duration of the strategy. 
Ministerial responsibility: The Minister for Health continues 
to have overall responsibility for the NDS. There also 
continues to be a Minister of State in the same department 
with responsibility for Health Promotion and the National 
Drugs Strategy. 
National Oversight Committee: This will be a senior official 
level committee ‘sponsored’ (p. 76) by the Minister of State 
for the NDS. Membership will include representatives from the 
statutory, community and voluntary sectors and expertise from 
both a clinical and academic representative. Membership from 
the statutory sector will be at the level of Assistant Secretary. 
The committee is to meet on a quarterly basis and has five 
main functions, as outlined in its terms of reference:
• To give leadership, direction, prioritisation and  
mobilisation of resources to support the implementation  
of the strategy.
• To measure performance in order to strengthen the 
delivery of drug initiatives and to improve the impact on 
the drug problem.
• To monitor the drugs situation and oversee the 
implementation of a prioritised programme of research to 
address gaps in knowledge.
• To ensure that the lessons drawn from evidence and good 
practice inform the development of policy and initiatives to 
address the drug problem.
• To convene subcommittees, as required, to support 
implementation of the strategy (p. 77). 
Standing subcommittee: A standing subcommittee will be set 
up to support the implementation of the NDS and promote 
coordination between national, local and regional levels. It 
will meet on a monthly basis and will be chaired by a senior 
official of the Department of Health. Membership will include 
representatives from the statutory, community and voluntary 
sectors. Its terms of reference are:
• To drive implementation of the NDS at national, local and 
regional level.
• To develop, implement and monitor responses to drug-
related intimidation as a matter of priority.
• To support and monitor the role of Drug and Alcohol Task 
Forces in coordinating local and regional implementation 
of the NDS with a view to strengthening the task force 
interagency model.
• To improve performance, promote good practice and build 
capacity to respond to the drug problem in line with the 
evidence base.
• To ensure good governance and accountability by all 
partners involved in the delivery of the strategy.
• To report to the National Oversight Committee on progress 
in the implementation of its work programme. 
PART 4
Implementing the drugs strategy
The final substantive chapter of the national drugs strategy 
(NDS) focuses on what is termed ‘strengthening the 
performance of the strategy’.1 There are two elements  
to this: measuring performance and the structures that  
will support the implementation of the strategy. 
Measuring performance
The strategy sets out a number of ways in which progress on 
the delivery of the strategy will be monitored and assessed:  
• A number of performance indicators appear at the end 
of each goal. However, the detail of which objective they 
relate to, how they will be used, and timelines for delivery 
are not included. 
• Bodies charged with delivering the different actions of 
the strategy will be required to report to the Minister with 
responsibility for the NDS on an annual basis. 
• The strategy aims to operationalise a new Performance 
Measurement System by 2020. The system that was 
developed by consultants will ‘support Reducing Harm, 
Supporting Recovery, improve accountability across the 
statutory, community and voluntary sectors and strengthen 
the Drug and Alcohol Task Force model’ (p. 74). It focuses 
on ‘the net effects of the strategy at the population level, 
in particular, the effects on the health wellbeing and 
quality of life of people living in local and regional DATF 
areas’ (p. 73). Essentially, it makes predictions about what 
it would expect the level of problem drug use to be in a 
small area, based on a selection of social indicators linked 
to deprivation, urbanity and social class. It then compares 
these with the predicted level of problem substance 
use. If the model finds significant changes over time, or 
differences are found between DATF areas, then analysis 
will be carried out to explore why this has happened.
Implementation structures
The new strategy makes some changes to the existing 
organisational structure for the implementation and delivery 
of the drugs strategy. Among the aims of the restructure 
are that the structure of the previous drugs strategy would 
be streamlined to better deliver on the key functions of the 
strategy; and that participation in the strategy would be 
optimised in a way that avoids ’duplication and overlap’ (p. 76). 
The Report of the rapid expert review of the National Drugs 
Strategy 2009—20162 identified the ‘strong role of community 
organisations’ in both strategy development and delivery as 
one of the ‘key features of the Irish context’ (p. 9). However, 
they noted that in some areas of the strategy, the coordination 
between local, regional and the national level became less 
effective over time. 
The new structures represent what is termed a ‘more 
streamlined structure’1 (p. 76). As with the previous strategy, 
the challenge will remain for the structures to be able 
New National Drug and Alcohol 
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Early Warning and Emerging Trends Committee: This 
committee will receive, share and monitor information  
from national and EU sources on new psychoactive 
substances of concern and any emerging trends and patterns 
in drug use and the associated risks. Membership of this 
committee is to be extended to include representatives of 
the network of coordinators of the Local and Regional Drug 
and Alcohol Task Forces. 
Drug and Alcohol Task Forces (DATFs): The current terms of 
reference of the DATFs are referred to in the strategy. Based 
on these, their role will continue to focus on assessing the 
extent and nature of the drug and alcohol problem in their 
areas and in coordinating action at local level so that there is a 
targeted response to the drug problem in local communities. 
They will continue to implement the NDS in the context of the 
needs of their region or local area through action plans. They 
will also provide an annual report on their activities to the 
Minister of State with responsibility for the NDS. It is envisaged 
that the new performance measurement framework will 
provide the DATFs with information that will support them in 
the delivery of their role. 
Lucy Dillon
1 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use  
in Ireland 2017 —2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
2 Griffiths P, Strang J and Singleton N (2016) Report of the rapid 
expert review of the national drugs strategy 2009—2016. Dublin: 
Department of Health. http://www.drugsandalcohol.ie/27289/ 
The strategy specifically requires drug-related intimidation to 
be on the agenda for the committee’s first meeting. Members 
are expected to develop what is called a ‘liaison relationship’ 
(p. 78) with task forces to support effective coordination and 
communication between delivery bodies and stakeholders at 
all levels.
Subcommittees: The national committee will be able to 
establish subcommittees to address specific issues and  
draw on any expertise necessary to support it on delivering 
its functions. 
Drugs Policy Unit, Department of Health: This unit will be 
responsible for:
• Analysing the implications of research findings for policy 
and design of initiatives to tackle the drug problem.
• Providing the national committee with advice on the 
commissioning of new research and development of new 
data sources, having regard to current information and 
research deficits and advice and changing patterns of drug 
use and emerging trends.
• Providing a secretariat to the committee and the standing 
subcommittee.
Health Research Board (HRB): The HRB will continue to 
be the EMCDDA’s national focal point. It will manage the 
commissioning of any research that the national committee 
decides should be undertaken to address gaps in their 
knowledge.
New National Drug and Alcohol 
Strategy launched continued
Figure 1: Structures supporting implementation of the new drugs strategy
Source: NSRF, 2016
Relevant Cabinet Committee
Minister of State for Health Promotion and the National Drugs Strategy
National Oversight Committee
Leadership / Direction / Prioritisation
Local and Regional Drug and Alcohol Task Force
Needs Assessment and Local Co-Ordination
Standing Sub-Committee
Implementation Support
Other Sub-Committees
As Required
Early Warning and 
Emerging Trends 
Sub-Committee
Health Research Board
Monitoring and Research
Department of Health 
Drugs Policy Unit
Analysis and Advice
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17 in these communities, impacting negatively on all aspects of 
community life’. Addressing the underlying issues causing drug 
use is essential ‘if we are serious about tackling the impact of 
problem drug use’.
Gay Health Network2 
The Gay Health Network (GHN) welcomed the specific 
mention, for the first time in the national strategy, of the 
need for targeted harm-reduction, education and prevention 
measures that are tailored towards the lesbian, gay, bisexual, 
transgender and intersex (LGBTI) community. It highlights 
actions dealing with the issue of chemsex (the use of drugs for 
or during sex). First, the need to provide addiction supports in 
non-traditional settings with particular reference to chemsex, 
and that it hopes this ‘signals a widening of resource provision 
for services attempting to bridge the gap between sexual, 
mental and addiction health’. Second, the inclusion of chemsex 
as a topic to be considered by the working group examining the 
evidence base for early harm reduction responses to current 
and emerging trends.
Simon Communities3 
Housing and homeless organisation, the Simon Communities, 
welcomed the new strategy, saying that the move to a more 
health-led approach will ‘save lives and reduce harm’, and that 
the inclusion of alcohol is ‘positive’. It notes in particular the 
introduction of the supervised injecting facilities. It welcomes 
the recognition in the strategy that people who are homeless 
are at a ‘far higher risk’ of problem drug use than those in 
secure housing and notes the complex relationship between 
homelessness and problematic drug and alcohol use. Both 
a harm reduction and recovery focus were identified by the 
Simon Communities as ‘at the heart of drug and homeless 
service provision’. It also notes the synergy with other 
Government strategies dealing with homelessness and that 
their successful delivery ‘depends not just on housing but also, 
crucially, on drug and alcohol, mental health, and community 
integration services being available’. While it welcomes the 
strategy and accompanying action plan, it calls for a more 
detailed implementation plan that would include targets and 
timelines ‘to enhance the Strategy’.
UISCE4
UISCE welcomed the new strategy. Its statement focuses on 
how ‘excited’ it is that ‘for the first time the voice of people 
who use drugs in Ireland has been captured and included in 
the development of the National Drug Strategy’, as well as 
now being represented in the implementation structures of 
the strategy for the first time. As with CityWide, it welcomes 
in particular the action to explore the alternative approaches 
to the possession of drugs for personal use. It also welcomes 
the establishment of a safe injecting facility, and the values of 
the strategy that see addiction as ‘a condition that requires 
compassion, understanding and seeing people as human beings’.
Lucy Dillon
1 CityWide Drugs Crisis Campaign (2017) Press release on the 
launch of the new national drugs strategy (NDS). http://www.
drugsandalcohol.ie/27700/
2 Gay Health Network (2017) Gay Health Network statement on 
national drug strategy 2017 —2025. http://www.drugsandalcohol.
ie/27701/
3 Simon Communities of Ireland (2017) Simon Communities welcome 
national drugs strategy publication. http://www.drugsandalcohol.
ie/27702/
4 Drugs.ie (2017) UISCE reacts to the launch of the national drug 
strategy 2017—2025. http://www.drugsandalcohol.ie/27703/ 
POLICY AND LEGISLATION 
Responses to the 
new drugs strategy 
A number of stakeholder agencies have published statements 
on the new national drug and alcohol strategy. These include: 
CityWide,1 Gay Health Network,2 Simon Communities3 and 
UISCE (Union for Improved Services, Communication and 
Education).4 The more health-led approach and the inclusion 
of alcohol in the strategy were widely welcomed. There 
were concerns, however, about how the strategy would be 
implemented in practice and the need for additional funding to 
do so. The statements are summarised below.
CityWide1
CityWide Drugs Crisis Campaign welcomed two elements 
of the strategy in particular: the establishment of a working 
group to look at alternative approaches to the possession of 
drugs for personal use; and the commitment to an integrated 
drug and alcohol policy. However, it has a number of concerns 
relating to the implementation of the strategy.
Integrated drug and alcohol strategy: It expresses concern 
that while there have been Government commitments to 
a joint policy in the past, this has often been ‘over-stated’ 
and has not been delivered in practice. It notes the ongoing 
opposition of the alcohol industry.
Funding: CityWide is concerned there will not be enough 
investment in services to be able to deliver on the range of 
actions laid out in the three-year action plan embedded in 
the strategy. It highlights that many of the strategy’s actions 
involve the ‘expansion and/or development’ of existing 
services, but that services are already operating on budgets 
that have been subject to numerous cuts over the last six 
years. Significant investment would therefore be required if 
actions are to be delivered. 
Interagency partnership: CityWide notes that interagency 
partnership has always been crucial to the implementation 
of Ireland’s drug strategies. While the new strategy says that 
it will remain a cornerstone of its implementation, CityWide 
argues that interagency partnership on drug issues ‘is no 
longer working effectively at either national, regional or local 
level’. It argues that Government departments and their 
agencies are where key policy decisions are now made, rather 
than within the interagency structures where communities are 
represented. For interagency partnership to work in practice, 
the new structures established by the strategy will need, from 
the very start, a ‘strong and proactive’ National Committee 
that ensures all stakeholders are held to account for their 
responsibilities in delivering on the strategy, and that the Drug 
and Alcohol Task Forces are adequately supported. 
Causes of problem drug use: CityWide identifies one of the 
most significant barriers to delivering on the new strategy as a 
failure to address the underlying causes of ‘serious community 
drug problems’. It reiterates the fact that problem drug use 
continues to be concentrated in areas characterised by high 
levels of social and economic deprivation. Over time, the drug 
problem has become ‘chronic, deep rooted and embedded 
9
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Public consultation 
for the new drugs 
strategy
The new national drug and alcohol strategy (NDS), Reducing 
harm, supporting recovery: a health-led approach to drug 
and alcohol use in Ireland 2017—2025,1 was informed by a 
number of inputs, including a public consultation process. 
The public were invited to provide feedback on what they 
thought of the 2009—2016 strategy and what issues should 
be considered in the development of the new strategy. They 
could provide this by making a written or oral submission 
to the Department of Health, completing a questionnaire, 
or attending one of six regional events. Submissions and 
questionnaires could be made or submitted over the phone, 
by email, by post, or through the Department of Health’s 
website. Furthermore, there was an event and questionnaire 
that specifically targeted young people. Report on public 
consultation undertaken to inform the new national drugs 
strategy was subsequently published in May 2017.2 
The process
The consultation was held over a six-week period between 
September and October 2016. Those who took part 
included the general public, Drug and Alcohol Task Forces, 
service providers, service users, voluntary organisations, 
members of political parties, and elected representatives. 
The number of consultation questionnaires received 
was 2,115; youth questionnaires was 265; other feedback 
or submissions was 211; and attendees at the regional 
events was 363. The views expressed through these are 
summarised in the report. It is structured around the five 
pillars of the 2009—2016 strategy — prevention, supply 
reduction, treatment, rehabilitation, research — with 
additional chapters to cover feedback on the structure and 
content of the NDS 2009—2016, and ‘youth feedback’. 
Key findings
The summary of the lengthy report (i.e. 227 pages) focuses 
on recurring themes from the process. These include:
• Coverage: The importance of alcohol as a major drug of 
misuse was identified and some participants thought it 
should be included in the new strategy. 
• Geographical coverage: Drug misuse was seen as 
a national problem, with a call for greater access to 
information, treatment and rehabilitation services for 
people irrespective of where they live. In addition, it was 
argued that the supply and widespread availability of drugs 
throughout the country needed to be addressed.
• Drug education and awareness: There was an appeal for 
more education programmes that were evidence based 
and could be delivered to children of primary school age. 
More public awareness campaigns were also called for.
• Medicinal cannabis: A recurring theme was that  
cannabis should be made available by prescription for 
medicinal purposes.
• Drug use as a health issue: Participants argued that 
people who use drugs should not be treated like criminals 
and that use should be treated as a health rather than a 
criminal issue.
• Stigma of being a user: Service users described the shame 
and stigma that goes with their addiction. They wanted to 
feel ‘the values of respect, compassion, and a sense of 
choice at the heart of services provided to them’ (p. 2).
• Debt intimidation and violence: These were identified  
as problems facing users and their families that needed to 
be addressed.
• Treatment availability: A need to increase and improve the 
availability of treatment and rehabilitation services across 
the country and to all groups was recognised. 
• Terminology: There was some suggestion that using 
language that is led by the substance's legal status is 
unhelpful (i.e. illicit) and that instead they should be 
defined as ‘harmful’. 
• Dual diagnosis: Participants identified the problem 
of gaining access to services for those who have dual 
diagnosis as an important issue for the new strategy  
to address. 
• Alternatives to methadone: There was a call for 
alternatives to methadone to be made available.
• Prescription medication: The misuse of prescription 
medication was described as widespread and problematic.
• Coordination of delivery: A need was identified for 
improved communication and coordination between 
statutory, community and voluntary sectors, as well  
as increased funding for those delivering services on  
the ground.
• Quality standards: These were identified as in need of 
improvement across the sector.
• Hidden harm: The needs of children and young people 
whose families/caregivers were affected by addiction  
were identified.
• Research: The need for good-quality evidence to inform 
the strategy and service delivery was identified.
• Family and community: The central role of families and 
communities in addressing local drug issues was discussed.
• Family support: There was a call for more support for 
families living with a family member’s addiction. 
Lucy Dillon
1 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017—2025. Dublin: Department of Health. http://www.
drugsandalcohol.ie/27603/
2 RPS Group plc (2017) Report on public consultation undertaken 
to inform the new national drugs strategy. Dublin: Department 
of Health. http://www.drugsandalcohol.ie/27489/
10
dr
ug
ne
t I
R
EL
AN
D
   
   
Is
su
e 
63
 |  
Au
tu
m
n 
20
17 By analysing the nature and level of provision of services in 
an area, we can begin to see what the impact of prevention, 
harm reduction or treatment programmes have had on the 
prevalence of problem substance use in that period of time. 
The difference may have been due to social or economic 
changes and these too can be identified. So, the framework 
takes into account the complex range of factors contributing 
to the problem substance use situation and the difficulty in 
relating changes in this situation over time to specific causes. 
We can also compare the levels of disparity between 
predicted and actual levels in different areas. When these 
levels of disparity differ between areas, comparisons 
between variables, such as service provision, in these areas 
provide further opportunity to identify causal factors. By 
identifying the reasons for differences in outcomes, we can 
get valuable information regarding the implementation of 
the strategy. This can also help DATFs improve their actions 
and interventions over time. The performance measurement 
framework includes a mechanism to enable funding to be 
allocated on a more equitable and rational basis, taking into 
consideration the underlying need in DATF areas. It is envisaged 
that, as the framework develops, it will be able to incorporate 
other problem substance use data sources and increase the 
precision of the system evaluating responses to this problem. 
Brian Galvin
1 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 2017—
2025. Dublin: Department of Health. http://www.drugsandalcohol.
ie/27603/
2 Haase T and Pratschke J (2017) A performance measurement 
framework for Drug and Alcohol Task Forces. Dublin: Trutz  
Haase — Social & Economic Consultants. Available online at  
http://www.drugsandalcohol.ie/27488/ 
3 Department of Health (2013) Healthy Ireland: a framework for 
improved health and wellbeing 2013—2025. Dublin: Department 
of Health. Available at www.drugsandalcohol.ie/19628
4 Small Areas are areas of population comprising between 50 and 
200 dwellings created by the National Institute for Regional and 
Spatial Analysis (NIRSA) on behalf of Ordnance Survey Ireland (OSi) 
in consultation with the Central Statistics Office (CSO). Small Areas 
were designed as the lowest level of geography for the compilation 
of statistics in line with data protection and generally comprise 
either complete or part of townlands or neighbourhoods. Available 
online at http://www.cso.ie/en/census/census2011boundaryfiles/
Performance 
measurement and 
resource allocation
In preparing Reducing harm, supporting recovery,1 the 
Department of Health commissioned a performance 
measurement system to help determine the impact of the 
strategy on problem substance use at a population level. 
A performance measurement framework for Drug and 
Alcohol Task Forces2 (DAFT) aims to capture how successful 
task forces are at reducing problem substance use within 
their own areas. This will help to identify both good practice 
and weaknesses in local responses and help to guide the 
allocation of resources to bring about better local services 
and systemic improvements. 
The approach taken in developing this system is consistent 
with the understanding of wellbeing in the Healthy Ireland3 
strategy. This approach goes beyond reporting outputs or 
reporting on progress in particular strategic actions and seeks 
to measure changes in the behaviours that lead to ill-health 
and threaten wellbeing. The drugs strategy has a number of 
population-based objectives and it is only by measuring the 
population effects of interventions that these objectives can 
be fully evaluated. This is what the authors of A performance 
measurement framework for Drug and Alcohol Task Forces 
set out to do. They developed a longitudinal framework to 
measure the impact of interventions on the level of problem 
substance use in task force areas. When effects at the local 
level are aggregated, the success of the strategy as a whole 
can be assessed. 
Measuring problem drug use in a Small Areas
The model at the core of the framework makes predictions 
regarding the level of problem drug use in a Small Area4 
based on a number of social indicators describing levels 
of deprivation, urbanity and social class. It then compares 
the predicted level with the actual prevalence of problem 
drug use as indicated in routine monitoring systems, such 
as treatment data. If differences are observed between the 
predicted level of problem substance use in an area and the 
actual levels over a period of time, we must then ask how has 
this change come about. 
be applied. Furthermore, it would not affect the law that makes 
the possession of drugs for sale or supply a criminal offence. 
CityWide believes that drug use is a social and health 
issue not a criminal justice one and it therefore supports 
decriminalisation.2 While it does not believe that 
decriminalisation is a ‘panacea for problem drug use’, it argues 
that the negative consequences of drug use are exacerbated 
by dealing with it through the criminal justice system. Current 
Government policy is also to ‘support a health-led rather than 
criminal justice approach to drugs use’ (p. 56).3 Furthermore, 
the new national drug and alcohol strategy includes an action 
‘to consider the approaches taken in other jurisdictions to the 
possession of small quantities of drugs for personal use with 
a view to making recommendations on policy options to the 
relevant Minister within 12 months’ (p. 58).4
CityWide’s 
evidence base for 
decriminalisation
In May 2017, CityWide Drugs Crisis Campaign launched a 
new area on its website dedicated to the evidence base for 
the decriminalisation of possession of drugs for personal 
use.1 Decriminalisation in Ireland would involve changing the 
current law that defines possession of drugs for personal use 
as a criminal offence. This does not mean that possession for 
personal use would be legal, as non-criminal penalties may still 
11
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Evidence base
A range of national data and policy sources are used to 
describe the situation in Ireland.5 The international elements 
of the website primarily draw on evidence from three 
overviews of the international situation and the impact of 
decriminalisation in countries where it has been introduced.6 
Core themes
There are a number of areas within the decriminalisation 
element of the website, each of which presents evidence on a 
core theme of the debate.
How criminalisation impacts globally 
Four key findings on the effects of criminalising drug 
possession for personal use were identified:  
• The level of drug use in a country is not directly related 
to the toughness of a country’s enforcement against drug 
possession, i.e. a tough enforcement regime does not 
reduce drug use.
• Criminalising drug use increases the health risks to which 
people who use drugs are exposed.
• Criminalising drug use creates social risk because society 
tends to see people convicted of drug offences as 
unproductive criminals. This stigmatisation can lead to 
discrimination, including reduced support for health-led 
responses.
• Punitive drug policies have a disproportionate impact on 
already vulnerable communities, and increase the health 
risks for entire populations.7
Current situation in Ireland 
This section of the website provides information on four key 
areas related to drug use in Ireland: the legislation governing 
the use of controlled drugs in Ireland; what happens in terms 
of law enforcement in relation to drug possession offences; an 
overview of the policy debate on decriminalisation in Ireland 
and how it has evolved since the 1990s; and the evidence on 
drug use in Ireland and its associated problems. 
Impacts of decriminalisation
Following on from the findings related to how criminalisation 
impacts globally, this area explores the effects of 
decriminalising drug possession for personal use. Three key 
findings were identified:  
• The level of drug use in a country is not directly affected 
by decriminalising drug possession and use. The available 
evidence shows neither an increase nor a decrease in the 
level of drug use.
• Decriminalisation is associated with improved health 
outcomes, as more people who use drugs feel able to 
access treatment. However, the evidence also indicates 
that other factors, such as improved harm reduction 
and treatment services, contribute significantly to the 
improved health outcomes.
• Decriminalisation leads to improved social outcomes 
as criminal justice system costs come down and as the 
prospects of those detected with drugs look up, e.g. 
in terms of employment and their relationships with 
significant others. Positive results have also been reported 
with regard to recovery and recidivism.8 
UN and decriminalisation 
The situation with decriminalisation and the United Nations 
(UN) is complex. On the one hand, member states need to 
comply with the UN drug conventions that are often cited as 
being prohibitive of decriminalisation. However, on the other 
hand, criminalising the possession of drugs for personal use 
‘breaches public health and human rights standards, which are 
also supported by the UN’. This section of the website explores 
this situation, noting that a number of key UN agencies have 
called for decriminalisation. 
Which countries have decriminalised and how? 
This section of the website explores the different models of 
decriminalisation that have been implemented internationally. 
It draws on a report by Release, a UK centre of expertise 
on drugs and drug law, that found ‘a surge toward this drug 
policy model in the past 15 years’.9 There is also a link to the 
e-tool developed by the International Drug Policy Consortium, 
which allows the user to compare models of decriminalisation 
globally (see also related article in this issue of Drugnet).
There is also a frequently asked questions section that 
includes definitions of key terms in the debate. The site can be 
accessed at: https://www.citywide.ie/decriminalisation/
Lucy Dillon 
1 The CityWide Drugs Crisis Campaign site on decriminalisation 
can be accessed at https://www.citywide.ie/decriminalisation/.
2 The term ‘decriminalisation’ will be used for the remainder of 
this article to refer to the decriminalisation of possession of 
drugs for personal use.
3 Department of the Taoiseach (2016) A programme for a 
partnership government. Dublin: Government Publications 
Office. http://www.drugsandalcohol.ie/25508/
4 Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017 —2025. Dublin: Department of Health. http://www.
drugsandalcohol.ie/27603/
5 Examples of the sources used include: the Irish Statute Book; 
Garda Recorded Crime Statistics from the Central Statistics 
Office; the Courts Service Annual Report; and the National Drug 
Treatment Reporting System. 
6 The three overviews used are: (a) Home Office (2014) Drugs: 
international comparators. London: Home Office, United 
Kingdom. http://www.drugsandalcohol.ie/22874/; (b) Office of 
the High Commissioner for Human Rights, United Nations (2010) 
Report of the Special Rapporteur on the right of everyone to 
the enjoyment of the highest attainable standard of physical 
and mental health. Geneva: Office of the High Commissioner for 
Human Rights, United Nations. Available online at http://www.
ohchr.org/EN/Issues/Health/Pages/SRRightHealthIndex.aspx;  
(c) Hughes C, Ritter A, Chalmers J, Lancaster K, Barratt M 
and Moxham-Hall V (2016) Decriminalisation of drug use and 
possession in Australia — a briefing note. Sydney: Drug Policy 
Modelling Program, NDARC, UNSW Australia. http://www.
drugsandalcohol.ie/25238/ 
7 CityWide Drugs Crisis Campaign (2017) What are the effects 
of criminalisation? Available online at https://www.citywide.ie/
decriminalisation/global.html
8 CityWide Drugs Crisis Campaign (2017) Impacts of 
decriminalisation. Available online at https://www.citywide.ie/
decriminalisation/impacts.html
9 Rosmarin A and Eastwood N (2012) A quiet revolution: drug 
decriminalisation policies in practice across the globe. London: 
Release. http://www.drugsandalcohol.ie/18327/
Decriminalisation evidence continued
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17 fight discrimination in relation to their functions and powers.4 
Therefore, ‘in preparing strategic plans, public sector bodies 
must assess and identify the human rights and equality issues 
that are relevant to their functions. These issues must relate 
to all of its functions as policy maker, employer and service 
provider’ (p. 4).6 Despite this, a human rights and equality 
assessment is not reported to have been carried out as part of 
the methodology used to develop the new strategy. 
Lucy Dillon
1 Pike B (2016) Drug users’ human rights. Drugnet Ireland, 58: 6—7. 
http://www.drugsandalcohol.ie/25958/
2 Pike B (2016) Human rights and drug policy —  
international perspectives. Drugnet Ireland, 58: 8—9.  
http://www.drugsandalcohol.ie/25959/
3 Pike B (2016) Service users’ rights. Drugnet Ireland, 58: 29.  
http://www.drugsandalcohol.ie/25990/ 
4 Dillon L (2016) Human rights, equality and the National Drugs 
Strategy. Drugnet Ireland, 58: 9. http://www.drugsandalcohol.
ie/25960/
5 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 2017—
2025. Dublin: Department of Health. http://www.drugsandalcohol.
ie/27603/
6  Irish Human Rights and Equality Commission (2016) The public 
sector duty: eliminating discrimination, promoting equality and 
protecting human rights. Dublin: Irish Human Rights and Equality 
Commission. http://www.drugsandalcohol.ie/27649/
Human rights and the 
new drugs strategy
Internationally, there has been a growing focus on adopting a 
human-rights-based approach to drug policy. This topic has 
been covered in previous editions of Drugnet Ireland both in 
the national and international context.1,2,3,4 With these articles 
in mind, there are a number of features of the new strategy 
that would suggest a more human-rights-based approach than 
in previous strategies:  
• It takes a health-led approach to drug use. 
• It is underpinned by the values of compassion, respect, 
equity, inclusion, partnership and evidence-informed. 
• It incorporates human rights in some elements, for example 
introducing supervised injecting facilities and exploring 
approaches to the possession of small quantities of drugs.
However, human rights are only specifically mentioned  
once in the document. This is in relation to developing a 
Quality Assurance Framework for the delivery of services (see 
action 4.2.435). 
Since the introduction of the Irish Human Rights and Equality 
Commission Act 2014, public bodies are required to take 
proactive steps to promote equality, protect human rights, and 
• Which interventions are effective in reducing the 
initiation, or continued use, of illicit drugs and related 
harmful behaviours among children and young people 
aged up to 25 years?
• Which interventions are effective in reducing harmful 
behaviours related to illicit drug use?
• Which interventions are effective in treating drug misuse 
among people who misuse or who are dependent upon 
illicit drugs?
• Which interventions are effective in supporting people 
who misuse illicit drugs to fully recover from their illicit 
drug misuse and become better reintegrated into the 
community following/alongside treatment?
Using the reviews to answer questions on 
responses in the drugs area
It is helpful to separate the findings of the reviews into what 
is known to work or not work and interventions of unproven 
efficacy thus far. This makes the findings quickly apparent. 
But demonstrating the scientific value of the work somewhat 
hides the value of the ‘review of reviews’ approach and its 
role in the development of an evidence baseline relevant to 
the Irish situation.
Below are some examples of how the review might be used 
to answer questions that are of interest to stakeholders.
HRB publishes  
review of reviews 
In 2015, the Health Research Board (HRB) commissioned the 
Public Health Institute at Liverpool John Moores University to 
prepare a report on the most recent international evidence 
on responses to problem drug use. This was to support 
the steering committee working on a new drugs strategy. 
Incorporating evidence into policy has been a concern of 
several countries developing drugs strategies in recent years. 
Part of this process is identifying responses that have been 
shown to work but, just as importantly, identifying what 
evidence is relevant to the national situation, where the gaps 
in evidence are, and what interventions are shown not to be 
effective or produce harmful results. 
Ensuring that a strategy is evidence based requires an 
acknowledgement that evidence is constantly improving 
and knowledge on effective responses will develop during 
the term of the strategy. A dynamic strategy supports this 
development and recognises the value of the evidence 
produced by the evaluative process built into responses. 
In July 2017, the HRB published The effectiveness of 
interventions related to the use of illicit drugs: prevention, 
harm reduction, treatment and recovery. A ‘review of 
reviews’.1 The ‘review of reviews’ approach provides an 
overview of the most recent high-quality evidence. The 
primary research questions for the review were:
13
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Question 4: How can evaluation be integrated into 
comprehensive community-based programmes aimed at 
preventing both licit and illicit substance use?
Measuring the effectiveness of a prevention intervention 
is difficult. As Germany’s National strategy on drug and 
addiction policy (2012)2 states:
The goal of prevention is to avoid the occurrence of 
an event, whether this means the initial consumption 
of a substance, the emergence of abusive behaviour 
or addiction. Monitoring success therefore involves 
measuring the non-occurrence of an event. This is 
the main reason why the evaluation of prevention 
measures is one of the most difficult areas to 
evaluate in terms of methodology.2 (p. 16)
The review identified a number of reviews of well-defined 
and rigorous programmes. Adapting programmes of this type 
locally presents challenges. However, the reviews included 
in the study also identify the outcomes used to measure the 
effectiveness of a prevention programme. 
A review from 2006 indicated that comprehensive 
community-based programmes are more effective than 
school or community-only-based interventions at preventing 
both licit and illicit substance use. This review listed a 
number of primary and secondary outcomes that were 
measured by the evaluations, including in this systematic 
review. This is useful in identifying outcomes which could be 
included in an evaluation of programmes of this type being 
implemented locally. 
Primary outcomes: 
• Numbers of people who stop using substances
• Frequency of substance use
• Numbers of people who start using substances
• Time before initiation of substance use
Secondary outcomes:
• Changes in pattern of substance, range of substances, or 
type of substance
• Changes in risk or protective factors: 
–  Knowledge 
–  Attitudes towards drug use 
–  School attendance 
–  Family cohesion 
–  Access to services
• Outcomes identified in various health programmes
• Engagement of community of vulnerable young people in 
the programme
• Drug-related illnesses
• Outcomes related to criminal justice system: 
–  Prosecutions 
–  Changes in antisocial or offending behaviour 
–   Outcomes identified in criminal justice programmes 
aimed at children
Question 1: How can young people be enabled to make 
sensible decisions about substance use or provide help to 
members at risk of abusing drugs or affected by drug use?
Family-based programmes are one of the most commonly 
used approaches internationally to prevent substance misuse 
in young people. These interventions can be aimed at all 
individuals (parents and young people) or just parents in 
a range of settings. Information on the harms of drug use 
and sessions on effective parenting, communication and 
discipline typically feature on these programmes. Currently, 
in Europe, those interventions involving the whole family 
are more likely to be recommended than those that train 
parents only. 
Findings from high-quality and medium-quality studies in 
the prevention review suggest that a combined parent-
and-child-intervention approach may be more effective 
at reducing cannabis initiation and use than interventions 
that target parents alone. Moderate-quality review 
level evidence from the treatment review suggests that 
multidimensional family therapy is effective for reducing 
drug use frequency and severity in comparison to other 
interventions among adolescents, including cognitive 
behavioural therapy (CBT), but is generally no more nor less 
effective for treatment retention.
Question 2: How do you reduce the risk of harm from drugs 
in a recreational setting, such as a nightclub?
High-quality evidence in the harm reduction review suggests 
that effective harm reduction activities in a recreational 
setting include staff training, law enforcement, user/patron 
prevention and harm reduction interventions. No evidence 
was identified on pill-testing kits or similar interventions 
for inclusion in this review, reflecting the lack of evidence 
available (at primary or review level) on this approach.
Question 3: How can treatment programmes increase the 
likelihood of reintegration and recovery?
The researchers were asked to pay particular attention to 
this topic, as it was anticipated that this would be of interest 
in the development of the strategy. With this in mind, they 
looked at reviews prior to 2010 and lower-quality reviews.
Medium-quality and low-quality evidence on recovery 
and reintegration interventions in the treatment reviews 
section of the report indicates that peer coaching, recovery 
housing, and mutual aid approaches may have benefits 
for substance use outcomes. Moderate-quality evidence 
indicates that residency in recovery homes was associated 
with improved employment, reduced criminal behaviour and 
substance use in comparison to ‘usual care’ treatments, but 
evidence on these outcomes was limited. Evidence indicated 
that peer-recovery coaching interventions were associated 
with reduced substance use in comparison to individuals 
receiving usual aftercare, but this evidence was limited by 
the quality of review and primary study evidence. There was 
moderate-quality evidence to suggest that continuing care 
may have a positive effect on substance use in comparison 
to control treatments.
Review of reviews continued
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17 • Couples-based therapy (Treatment review): Moderate-
quality review evidence indicates that couples-based 
interventions are more effective than relapse-prevention 
CBT for achieving abstinence.
• Multisession psychosocial interventions (Harm reduction 
review): Moderate-quality evidence suggests that 
multisession psychosocial interventions aimed at people 
who inject drugs may have beneficial impacts on sexual 
risk behaviours, but not on injection risk behaviours. 
Evidence regarding behavioural interventions was limited 
and based on small numbers of primary studies.
Interventions for people who come in contact 
with the criminal justice system
There is good evidence for only a limited number of 
interventions in this setting. However, contact with the 
criminal justice system through arrest, probation or 
incarceration presents opportunities for preventative and 
harm reduction interventions. These can complement 
existing treatments:  
• HIV risk reduction (Harm reduction review): Moderate-
quality evidence indicates that improving accessibility 
to HIV testing through onsite testing in probation and 
immediate next day testing in prison is associated with an 
increased uptake of HIV testing.
• Psychosocial interventions in prison (Treatment review): 
There is some evidence to suggest that treatment 
through prison-based therapeutic communities reduces 
drug relapse and criminal activity among prisoners. There 
is no consistent evidence to support other treatment 
types for this population, including drug courts, boot 
camps and psychosocial interventions, although there 
was limited and low-quality review level evidence 
supporting meditation-based treatment. 
Brian Galvin
1 Bates G, Jones L, Maden M, Cochrane M, Pendlebury M, Sumnall 
H (2017) The effectiveness of interventions related to the use 
of illicit drugs: prevention, harm reduction, treatment and 
recovery. A ‘review of reviews’. Dublin: Health Research Board. 
http://www.drugsandalcohol.ie/27253/
2 Drug Commissioner of the Federal Government (2012) 
National strategy on drug and addiction policy. Berlin: 
Drug Commissioner of the Federal Government [Die 
Drogenbeauftragte der Bundesregierung]. Available online at 
http://www.drogenbeauftragte.de/
Using the reviews to identify gaps in the evidence
The review identifies gaps in the evidence and areas where 
further exploration is needed. We can only determine which 
evidence gaps are relevant when it is decided what questions 
need to be answered. There are several areas covered by the 
review where the evidence is inconclusive. This may because 
of the low number of studies in this area, the lack of quality 
evaluations, or the quality of the reviews that have looked 
at these evaluations. A decision on whether to support a 
particular intervention should not be based solely on the 
evidence available in a high-level review. There will always 
be responses for which we do not have strong evidence to 
support them. That is the nature of this type of work. This 
presents an opportunity to contribute to the knowledge base 
on an intervention using carefully constructed evaluations. 
Many of the studies included in reviews, while not presenting 
conclusive evidence, can support this process, as they will 
have identified appropriate outcomes which can be used to 
measure the effectiveness of the response.
Psychosocial treatments
It is good practice to provide access to evidence-based 
and well-designed psychosocial interventions (based on 
behavioural, cognitive, motivational and social theories) in 
addition to standard care or in conjunction with existing 
pharmacological drug treatments. The review provides 
evidence of effectiveness on many types of psychosocial 
treatments, including the following interventions: 
• Brief interventions (Prevention review): While evidence 
on the effectiveness in drug prevention is scarce, 
there is substantial evidence to suggest that brief 
interventions may be effective in alcohol prevention. 
Brief interventions are applied to recreational users 
or individuals at risk of misusing drugs; however, for 
individuals, who are already misusing substances, a brief 
intervention may not be appropriate or sufficient to 
change an established behaviour.
• Cognitive behavioural therapy (Treatment review): 
Moderate-quality evidence suggested that CBT is 
generally more effective for outcomes relating to 
cannabis use and dependency in comparison to 
individuals receiving no treatment, but no more nor 
less effective than other interventions. When combined 
with contingency management, low-quality evidence on 
the effectiveness of CBT was mixed and inconclusive in 
comparison to other interventions.
Review of reviews continued
Trends analysis  
of drugs situation  
in Ireland
The Health Research Board commissioned the Public Health 
Institute at Liverpool John Moores University to prepare a 
trends analysis on the drugs situation in Ireland. The drugs 
situation in Ireland: an overview of trends from 2005 to 20151 
reviews the current drug situation in Ireland, analysing 10 years 
of data up to the most recent data available, with respect 
to the five European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) key indicators (prevalence of drug use, 
high risk drug use, treatment demand, drug-related deaths, 
and mortality and drug-related infectious diseases) as well as 
drug-related crime and supply. In addition to presentation 
of national trends, this report includes additional evidence 
looking at trends in data relating to specific subpopulations, 
including people who inject drugs, prisoners, homeless 
individuals, sex workers and the Traveller community. 
Brian Galvin
1 Bates G (2017) The drugs situation in Ireland: an overview  
of trends from 2005 to 2015. Liverpool: Public Health  
Institute, Liverpool John Moores University.  
http://www.drugsandalcohol.ie/27254
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College Dublin (UCD). Conference host committee members 
included representatives from the Health Research Board; 
Trinity College Dublin; Dublin City Council; National Advisory 
Committee on Drugs and Alcohol; Dublin Town; Irish Family 
Planning Association; SpunOut; Ballymun Local Drug and 
Alcohol Task Force; Health Service Executive; Institute of 
Public Health in Ireland; CityWide Drugs Crisis Campaign; An 
Garda Síochána; and the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA). 
Key to the success of the conference was the support from 
the Department of Health, particularly in the provision of the 
first-class Printworks Conference Centre at Dublin Castle. 
International conference partners included the Public Health 
Institute at Liverpool John Moores University; Public Health 
Wales; and the European Institute of Studies on Prevention 
(IREFREA), Portugal. Support from these agencies contributed 
to the strong multidisciplinary aspect to the conference, with 
keynote speeches and parallel sessions covering a wide range 
of substance use-related and harm reduction topics. These 
included pill testing, new psychoactive substances (NPS), 
prescription drug use, and substance use-related prevention 
and education. With 12 keynote speakers, conference 
attendees also had access to a significant range of expertise 
over the duration of the conference. 
Conference themes
Club Health Dublin 2017 covered a range of themes related 
to healthy nightlife. Although substance use was a core focus, 
related and intersecting issues such as policing, violence, 
terrorism, sexual health, and sexual violence were also 
covered. A new theme for Club Health Dublin 2017 was that 
of social exclusion, with abstracts sought on nightlife issues 
in the context of social disadvantage and the crossover 
between such contexts and more mainstream night-time 
settings. A dedicated conference parallel session considered 
discrimination, marginalisation and mobilisation, with a range 
of papers presented that examined harm reduction in private 
party spaces, alcohol use by young people, community alcohol 
mobilisation, young people and cannabis use, and community 
drug checking in response to the fentanyl crisis. It is hoped this 
theme will continue on in Club Health 2019, as a converging 
of club, festival and socially related drug issues and those 
traditionally connected to problematic substance use emerges 
in many countries.
Club Health Dublin 
2017: conference 
overview and 
highlights
The 10th Club Health International Conference on Nightlife, 
Substance Use and Related Health Issues took place in the 
Printworks in Dublin Castle on 24—26 May 2017.1 It marked 
20 years of Club Health conferences and was the first time 
the conference was held in Ireland. Club Health conferences 
enable researchers, practitioners and experts from a wide 
range of fields to meet, present and exchange on current and 
emerging evidence, policy and practice relating to protecting 
and promoting health in urban night-time settings as well as 
music festivals and holiday destinations with a clubbing or 
nightlife emphasis. 
Club Health began in 1997 in Liverpool, a city that twinned 
with Dublin also in 1997. It has been hosted in partnership 
with organisations, government departments and agencies in 
many countries ever since, including the Netherlands, Italy, 
Australia, Slovenia, Spain, the Czech Republic, Switzerland, 
the USA, and in 2015 in Lisbon, Portugal. A critical focus of 
all Club Health conferences is the interdisciplinary nature of 
the presentations and attendees, with the 2017 conference 
attracting 151 international participants from 20 countries in 
addition to attendees from Ireland. Conference attendees 
were from a very broad range of occupations and sectors, 
including city councils, police forces, forensics, pharmacy, 
medicine, health promotion, drug and alcohol treatment 
settings, and the night-time economy sector. There were 12 
keynote presentations, over 90 parallel session presentations, 
and 15 poster presentations at the conference in Dublin. 
Partnership with key agencies
An important aspect of Club Health Dublin 2017 was the 
partnership with key agencies in hosting and supporting 
the conference. The conference organising hub was based 
within the Community Drugs Programme in the School of 
Social Policy, Social Work and Social Justice in University 
Members of the organising committee 
for Club Health 2017: (L to R) Siobhán 
O'Brien Green, Chris Luke, Hilda 
Loughran, Sarah Morton, Karl O'Brien 
and Andrew Bennett 
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17 ‘It was another great Club Health conference. I came 
away very re-inspired.’
‘Many thanks for your work towards the conference; 
I found it very useful. Look forward to next year!’
‘It was a pleasure to see you all in Dublin — really 
nice conference, well done.’
‘Many thanks again for an amazing Club Health 
Conference in Dublin this year. It was great to see 
how all the efforts you took with regard to this 
project were paying off — the organization was 
incredibly good!’
‘Thank you again for the opportunity to speak at the 
conference; it has given me confidence to expand 
on my Club Health ideas! I look forward to hopefully 
attending the next conference.’
‘Congratulations on a fantastic conference, it was 
very well organised and very enjoyable.’
‘Thank you for hosting this — [it] was such an 
interesting conference and [I] went away newly 
enthused and encouraged about my practice …  
so thank you.’
‘Thank you and congratulations to you and your  
team for the well-organized Club Health conference 
in Dublin.’
Legacy actions
It is hoped that lessons, highlights and emerging topics will 
inform the programme for the next Club Health Conference 
in 2019. Organising committee members Andrew Bennett and 
Sarah Morton will present on a panel session proposed and 
chaired by the EMCDDA at the Lisbon Addictions Conference 
2017 on the topic of ‘Nightlife: no risk no fun? Challenges 
for drug prevention and trendspotting’. Andrew Bennett 
will present on ‘Protecting and promoting health in nightlife 
environments during the last three decades’ and Sarah Morton 
will present on ‘Emerging trends within nightlife settings: 
Responses and innovation’, based on outcomes from Club 
Health Dublin 2017. Looking to the future, we plan to continue 
to build alliances and share knowledge and experiences  
with the Club Health Dublin 2017 partners, presenters  
and delegates.
Sarah Morton and Siobán O’Brien Green
1 For further information, visit  
http://theclubhealthconference.com/ 
An Irish focus
A number of excellent abstracts was submitted by Irish 
researchers, practitioners and those involved in policy. In 
total, 15 Irish papers were accepted for the conference 
programme, with a further three Irish speakers delivering 
keynote addresses: Dr Chris Luke, Mercy University Hospital; 
Dr Fiona Lyons, Health Service Executive; and Dr Sarah Morton, 
UCD. The topics of the papers delivered within parallel sessions 
were divided into those that arise regularly in relation to harm 
reduction in the night-time environment — such as policing, 
public health, pill testing, harm reduction campaigns, and 
NPS testing and responses — and those that are emerging 
and relate to night-time contexts — such as chemsex and 
responses within and to certain communities, e.g. lesbian, gay, 
bisexual and transgender (LGBT) — as well as social exclusion. 
As with the broader conference trend, papers were presented 
by a range of researchers, practitioners and those working at 
the practice and/or policy interface. 
Conference highlights
The three-day conference concluded with a final reflection on 
conference highlights and learning points, with a discussion 
panel selected from the delegates. Key points made during this 
session included:
• The value of having such an interdisciplinary approach to 
considering harm reduction in the night-time environment, 
particularly the value of pharmaceutical and toxicology 
expertise.
• The focus on alcohol harms, education, prevention and 
harm reduction, and the level of expertise, research and 
practice knowledge available to delegates.
• The importance of the social exclusion theme, which 
was named as a welcome addition to the Club Health 
programme.
• The combination of research and practice, particularly 
the sharing of examples of developing and enacting 
interventions based on research evidence.
• The presence of international expertise in relation to pill 
testing and pill-testing festival interventions.
Notably, there was a very high attendance rate of delegates 
each day, with lively discussions and networking during breaks 
and between sessions, indicating the value of the range of 
speakers. Feedback and comments from delegates included:
Club Health 2017 continued
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Inaugural 
international 
conference marks 
Recovery Month
The first international conference in Ireland on recovery from 
drug addiction, Mainstreaming Recovery in Irish Drug
Policy and Practice: the Challenge of Change, took place in 
Trinity College Dublin (TCD) on 8 September 2017. Organised 
by the Recovery Academy of Ireland, it was one of a number 
of events held during International Recovery Month to 
recognise, promote and celebrate recovery from addiction. 
The conference heard international perspectives based on 
academic research; evidence that recovery works; insights 
into the recovery response in Scotland where addiction 
services have embraced a recovery model; lessons from 
the mental health recovery movement in Ireland that could 
be applied to addiction recovery; and personal stories of 
recovery journeys.
Professor David Best of Sheffield Hallam University gave  
the keynote address. Best is a leading figure in international 
research around recovery from drug and alcohol addiction 
and related policy issues. He believes that recovery is 
fundamentally an issue of social justice. It is about changing 
behaviour, building positive and supportive social networks 
and creating an open door to reintegrate the person in 
recovery. International studies that show what works are the 
following: dedicated recovery housing; mutual aid; peer-
delivered interventions; support networks of sober friends; 
spending time with other people in recovery; and, spending 
time actually doing things such as childcare, engaging in 
community groups, volunteering, education, training,  
and employment.
Professor Agnes Higgins, a specialist in mental health nursing 
in the School of Nursing and Midwifery in TCD, said that 
traditionally recovery in mental health was understood 
as symptom management (cure, care and containment). 
Increasingly, however, it is being seen as a personal process 
of learning, discovery and growth, often described by the 
acronym CHIME: connection, hope, identity, meaning and 
empowerment.
She shared a number of lessons from the mental health 
recovery movement which could also apply to addiction 
recovery. The most important was to understand that 
recovery is a way of being and relating. It was also important 
to note that changing the services culture takes time and 
involves challenging values, beliefs, prejudices and fears. She 
recommended bringing services together to share ideas and 
bringing staff, service users and families together to build 
a shared understanding of what recovery means and how it 
can be achieved.
The conference heard an important contribution from Brian 
Galvin, senior information specialist at the Health Research 
Board. He outlined an initiative to create a shared framework 
which drug and alcohol services could use to measure 
recovery outcomes. The framework is still in development 
stage. Some of the outcomes to be measured will include 
attitude and feelings, employment and skills, relationships, 
personal circumstances and needs, and drug use behaviour. 
A pilot project will now occur in selected task forces using 
appropriate IT systems, agreed measurements and tools, 
staff training and results analysis. In particular, the service 
user will be encouraged to have a sense of ownership of  
the process.
Dharmacarini Kuladharini, chief executive of the Scottish 
Recovery Consortium, spoke about the Road to Recovery, 
the Scottish government’s drug strategy, published in 
2008, which took as a fundamental principle that people in 
addiction services could lead a purposeful and meaningful 
life. The strategy transformed drug and alcohol services in 
Scotland, created new responses and built shared alliances. 
Part of the response by the Scottish Recovery Consortium 
was to make lived experience visible at every level both 
within addiction services and the wider society. We changed 
the language, Kuladharini said. People were no longer service 
users or addicts but recovery activists.
The response also included employing people in recovery, 
organising a vibrant annual recovery walk and using recovery 
centres, pop-up cafés and colleges to mobilise people in 
Fergus McCabe and Professor Joe Barry 
of TCD in discussion at the recovery 
conference
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17 When I was 16, I had a Junior Cert and an opiate 
addiction. Nothing changed for me since I went 
on methadone. Twenty years later, when I came 
off methadone I had a Junior Cert and an opiate 
addiction… People don’t realise the effect of 
methadone. It puts the light inside you out. You’re 
just dead.
Now six years clean and sober, Pearse has trained as a 
recovery coach and is completing a university degree. 
Claire, another recovery coach who is now employed  
and works with women in recovery, also shared her  
recovery journey.  
What has recovery given me? It’s given me back a life 
with a whole new purpose and opportunities that I 
never could have dreamed of...Most importantly, it 
has given me a sense of feeling part of something. 
For years in active addiction, I was disconnected and 
had no sense of belonging to anything. Today I am a 
member of a recovery community.
A full conference report and slides of presentations can be 
found on the Recovery Academy of Ireland website at www.
recoveryacademyireland.ie. The Academy can be contacted 
at recoveryacademyire@gmail.com
Gerry McAleenan
recovery. In addition, there are workbooks and literature 
to support people in recovery and over 1,200 mutual aid 
meetings each week, more than the number of GP surgeries 
in Scotland.
As a result of the strategy, the response from treatment 
services and the efforts of people in recovery themselves, 
Scotland now has a thriving recovery movement with a 
multitude of vibrant recovery communities across the 
country. 
Recovery as an issue of social justice was raised by several 
speakers at the conference, including Best. Roisín Shortall, 
TD, a long-time social justice advocate who chaired the 
conference, noted that there were about 9,600 people  
on methadone maintenance, some for more than 10 years, 
but that there had been little or no thought at policy level  
as to what should happen to them next. She said that 
Ireland as a society needed to be much more ambitious 
about people with addiction, recognise that they have huge 
potential and provide the supports so they can move out  
of addiction to recovery. 
As with any social issue, it is the personal story that brings it 
alive. Pearse described the gains of 20 years on methadone:
Recovery conference 2017 continued
The e-tool aims to map out how these models work in 
practice and allows the user to explore the differences 
between each policy. For each model, it does this by 
describing their legal framework, the role of the police (if any), 
the judicial or administrative process, the applicable sanction 
(if any), and providing examples of countries illustrating each 
model. It makes a distinction between decriminalisation that is 
de jure (i.e. decriminalisation enshrined in law) and that which 
is de facto (i.e. drug use remains a criminal offence by law, but 
no prosecutions take place in practice). The e-tool is available 
at http://decrim.idpc.net/
Lucy Dillon
1 For more information on the IDPC, visit http://idpc.net
2 CityWide Drugs Crisis Campaign website area on 
decriminalisation can be accessed at https://www.citywide.ie/
decriminalisation/
An e-tool to 
map models of 
decriminalisation
The International Drug Policy Consortium (IDPC) is a global 
network of 163 non-governmental organisations (NGOs).1 
It focuses on issues related to drug production, trafficking 
and use, promoting objective and open debate on the 
effectiveness, direction and content of drug policies at 
national and international levels. The network supports 
evidence-based policies that are effective at reducing drug-
related harm. In collaboration with their NGO partners, in July 
2015, the IDPC launched an e-tool designed to map out the 
models of decriminalisation for drug use or possession of drugs 
for personal use globally. The IDPC identified 21 countries and 
jurisdictions that had adopted this legal position. There is also 
a link to the tool through the recently launched CityWide Drugs 
Crisis Campaign website area on decriminalisation discussed in 
another article in this issue of Drugnet.2
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PREVALENCE AND CURRENT SITUATION
Report from 
Blanchardstown’s 
drugs and alcohol 
trends monitoring 
system
On 18 May 2017, Blanchardstown Local Drug and Alcohol 
Task Force (BLDATF) launched its report Drug and alcohol 
trends monitoring system (DATMS) 2017: Year 2.1 BLADTF 
started the DATMS in 2015 to ensure they had a ‘thorough, 
comprehensive and deep knowledge of the problems of 
the [Dublin 15] area’ (p. 3) upon which to base decisions 
about service provision. This is the second annual report 
from the system.2,3 The system was designed to identify 
trends in patterns of drug use, and the authors caution 
that this requires three years of data. Therefore, any 
changes identified in the current report will require further 
investigation in the next rounds of data collection.
Methodology
The DATMS uses a mixed-method design, drawing on both 
primary and secondary data sources. Primary data sources 
included drug treatment data and data on at-risk under 
18–year-olds. Data collection included interviews with 
treatment service users and outreach workers administered 
questionnaires in the local community. The team also 
collected extensive data on drug litter in the area, focusing 
on its visibility, locations for drug use, and types of drugs 
used and methods of administration. The data have been 
visually represented on a map of Dublin 15 that accompanies 
the published report. 
Key findings
Below are the key findings from the report as they appear in 
its Executive Summary. 
Treated drug use
• Treated drug use in Dublin 15 is increasing.
• The number of drug users aged under 18 years and aged 
35 years and over in treatment is increasing.
• The number of Irish and non-Irish drug users in 
treatment is increasing.
• The number of Irish Traveller drug users in treatment is 
decreasing.
• Cannabis, alcohol, cocaine powder, and 
benzodiazepines/Z-drugs are the biggest problem for 
drug users aged under 18 years; the use of these drugs is 
increasing among this age group.
• Heroin, cannabis, alcohol, cocaine powder, 
benzodiazepines/Z-drugs, and methadone are the 
biggest problem for adult drug users.
• Heroin users are getting older, with few young people 
treated for this drug.
• The use of the following drugs is increasing among adult 
drug users: alcohol, cannabis, benzodiazepines/Z-drugs, 
powder and crack cocaine, Lyrica, and oxycodone.
• Polydrug use is the norm for the majority of treated  
drug users.
• Steroids and skin-tanning drugs are creating new hazards 
in Dublin 15.
Untreated drug use
• Alcohol, cannabis, MDMA, cocaine powder, and ketamine 
are the main drugs of use for untreated under 18-year-
olds and adult drug users.
• Cocaine powder use is increasing among untreated under 
18-year-olds and adult drug users.
• Cannabis resin use is increasing among Irish Traveller 
untreated drug users.
• Polydrug use is the norm for untreated under 18-year-
olds and adult drug users; alcohol is an integral part of 
polydrug use.
• Drugs are mostly used at the weekend and the frequency 
of use is age dependent, with adults reporting more 
regular use.
Factors contributing to drug use
• Drugs and alcohol are easily accessed in Dublin 15.
• Alcohol, benzodiazepines/Z-drugs, cannabis resin, Lyrica, 
and oxycodone are increasing in availability.
• The internet continues to facilitate drug distribution and 
the darknet is a factor in availability.
• Drug use is normalised among some peer, family and 
work groups.
• A common perception is that drugs are widely used and 
risk free.
• The family context:
–   Children’s education is being compromised by parental 
drug use.
–  Some drug use in Dublin 15 is intergenerational.
Consequences of drug and alcohol use
• Mental health:
–   Mental health disorders among treated adult drug 
users are increasing.
–   Mental health disorders among under 18-year-olds in 
Dublin 15 are increasing.
• Drug-related crime:
–   Drug dealers are getting younger and dealing occurs in 
schools.
–   Drug debt intimidation continues to be an issue for 
young people and adults.
• Social consequences:
–   Homelessness and poverty are increasing among drug 
users.
–   Drug use in schools is increasing and causing greater 
damage to education and leading to more exclusion.
–   Due to these social consequences rehabilitation is 
getting harder.
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17 • There is limited access to buprenorphine treatment for 
opiate dependence in Dublin 15.
• There is a lack of access to educational psychological 
assessments for children from preschool age to 
secondary school age. This issue particularly affects 
people from disadvantaged backgrounds with no 
resources to fund private assessments.
• A number of service providers reported a lack of 
awareness about addiction services in Dublin 15.
Lucy Dillon
1 Blanchardstown Local Drug and Alcohol Task Force (2017) Drug 
and alcohol trends monitoring system (DATMS) 2017: Year 2. 
Dublin: Blanchardstown Local Drug and Alcohol Task Force. 
http://www.drugsandalcohol.ie/27339/ 
2 Blanchardstown Local Drug and Alcohol Task Force (2016)  
Drug and alcohol trends monitoring system (DATMS) 2016. 
Dublin: Blanchardstown Local Drug and Alcohol Task Force.  
http://www.www.drugsandalcohol.ie/25281/ 
3 McGuire V (2016) Drug and alcohol trends in Blanchardstown. 
Drugnet Ireland, 58: 14. http://www.drugsandalcohol.ie/25963/ 
Drug litter
• Drug litter is widespread throughout Dublin 15.
• The largest concentrations of drug litter are outside 
areas traditionally associated with drug use, indicating 
many more drug users than are using services.
• Most drug litter relates to untreated drug use.
• Drugs are being used in hidden and inaccessible sites, 
increasing the hazards associated with drug use; many 
hidden sites are well developed and regularly used.
Gaps in service provision identified by research participants
• Access to mental health services is not improving, 
especially for young people.
• The prescribing of addictive medication requires 
regulation.
• Ex-service users working in the area are struggling 
without adequate supervision.
Blanchardstown monitoring continued
In the last decade, an increasing trend in cannabis use is 
evident among Irish 15-34-year-olds, with 23.8% reporting 
cannabis use in their life in the 2002/2003 survey compared 
to 33.5% in this survey. A similar trend is seen in a number 
of other Northern European countries (Finland, Denmark, 
France, Germany and Sweden).7
Cannabis in first-time drug treatment entrants
As cannabis use has risen in the population so too has 
the number of people seeking specialised treatment for 
cannabis-related problems. Data on first-time entry into 
drug treatment services by cannabis users was published 
by EMCDDA-based Montanari and colleagues at Maastricht 
University in 2017.6 Information about people entering 
specialised drug treatment in 22 European countries, 
including Ireland, was included in the paper.* Specialised 
drug treatment was defined as people attending outpatient 
or inpatient centres, low threshold agencies, general 
practitioners (GPs) or treatment centres in prison in all 
participating countries. Irish data relevant to this paper 
were collected by the National Drug Treatment Reporting 
System (NDRTS) at the Health Research Board and routinely 
sent to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). 
Cannabis was the problem drug used by approximately 
30% of clients entering specialised drug treatment in 2014 
across the 22 European countries (116,673 out of 400,125 
admissions). Focusing on first-time treatment entrants 
alone, cannabis users accounted for 46% of all new entrants 
in 2014, with the highest numbers recorded in the UK, 
Germany, Spain and France. It is also important to note 
that the number of first-time cannabis treatment entrants 
has risen from 29% in 2003. In 2014, Ireland ranked eighth 
highest for the number of first-time cannabis treatment 
admissions (1,696).
Cannabis use in 
Ireland within the 
European context
Cannabis is the most widely used illicit drug in Europe 
and worldwide.1 While increased mortality rates are not 
associated with cannabis use, a number of very serious 
and long-term negative health problems are correlated 
with regular and long-term cannabis use. These include 
dependence, mental illness, cognitive impairment, 
cardiovascular disease and pulmonary disorders, including 
lung cancer and chronic obstructive pulmonary disease.2 
Cannabis use in Ireland
The National Advisory Committee on Drugs and Alcohol 
(NACDA) published data on drug use in Ireland in 2016.3 The 
survey found that cannabis is the most commonly used illicit 
drug in Ireland in both genders and across all age groups, 
regardless of lifetime, last year or last month use. The results 
of the survey, completed in 2014/2015, are representative 
of the general population. Of note, 28% of all adults (15—64 
years) had used cannabis in their life, with 4.4% of these 
having used in the month prior to completing the survey.3,4 
This is higher than the European average lifetime cannabis use, 
which stands at 26.3%.5
* The 22 European countries included in the study are 
Bulgaria, Cyprus, Czech Republic, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia,  
Lithuania, Luxembourg, Malta, Portugal, Romania,  
Slovakia, Slovenia, Spain, the Netherlands,  
United Kingdom and Turkey. 
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Limitations of the study
These include population-related bias; potentially low 
reporting rates of GPs and other service providers; lack 
of a ‘synthetic cannabinoid’ option at the treatment level, 
which means that all cases are classed as cannabis; and the 
fact that this paper looks at cannabis alone, as opposed 
to entrants seeking treatment for polydrug use including 
cannabis in the list of problem drugs. A lack of quality control 
of the data is also cited as a limitation, as the data are 
collected in each country independently and then reported 
centrally to the EMCDDA. 
Conclusions
This data highlight the growing trend of cannabis use in 
Ireland and Europe, as well as the increasing demand for 
treatment of cannabis-related problems. In terms of service 
provision, the needs of cannabis users are very different to 
those of opioid users, which have typically been the focus of 
public health interventions across Europe. This data should 
be used to inform policy-makers and service providers to 
help address this ever-growing problem. 
Thérése Lynn
1 United Nations Office on Drugs and Crime (2017)  
World drug report 2017. Vienna: United Nations.  
http://www.drugsandalcohol.ie/27436/
2 Hall W, Renstrom M and Poznyak V (eds) (2016) The health and 
social effects of nonmedical cannabis use. Geneva: World 
Health Organization. http://www.drugsandalcohol.ie/25267/
3 National Advisory Committee on Drugs and Alcohol (NACDA)  
and Department of Health (UK) (2016) Prevalence of drug  
use and gambling in Ireland and drug use in Northern Ireland. 
Bulletin 1. Dublin: NACDA and Department of Health (UK).  
http://www.drugsandalcohol.ie/26364
4 Millar S (2017) Results from fourth general population survey  
on illicit drug use in Ireland. Drugnet Ireland, 60: 1—5.  
http://www.drugsandalcohol.ie/26697/
5 European Monitoring Centre for Drugs and Drug Addiction 
(2017) European drug report 2017: trends and developments. 
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/27401/
6 Montanari L, Guarita B, Mounteney J, Zipfel N and Simon R (2017) 
Cannabis use among people entering drug treatment in Europe: 
a growing phenomenon? European Addiction Research, 23(3): 
113—121. http://www.drugsandalcohol.ie/27310/
7 European Monitoring Centre for Drugs and Drug Addiction (2017) 
Country drug report 2017: Ireland. Luxembourg: Publications 
Office of the European Union. http://www.drugsandalcohol.
ie/27404/
 
In Europe, the annual number of first-time cannabis 
treatment entrants has increased each year, with an average 
annual percentage change (AAPC) of 6.1% between 2003 
(32,178) and 2014 (67,444). While Ireland experienced 
fluctuations in the numbers of first-time cannabis treatment 
entrants between 2003 and 2006, there has been an 
increase in the number of admissions since 2006 (Figure 
1). From 2003 to 2006, there was an annual percentage 
change (APC) of -6.23%, and from 2006 to 2015 there was an 
increase of 11.70% per year. Taken together, Ireland is above 
the European average with a 6.55% AAPC, between 2003 
(982) and 2014 (1,696). 
In terms of general admission to specialised drug treatment 
centres in Ireland (first-time and repeat entrants), cannabis 
accounted for 28% of overall admissions in Ireland in 2015, 
following heroin (41%).7 
Importantly, the paper states that the increases in first-time 
cannabis admissions do not appear to be due to an overall 
rise in admission numbers for primary illicit drug problems. 
The authors also identify a number of potential reasons 
for the European-wide increase in first-time treatment 
entrants for cannabis use, including an increase in population 
awareness of the risk of cannabis use, an increase in the 
offer and availability of drug treatment across Europe, and 
an increase in the prevalence and potency of cannabis and 
synthetic cannabinoids, resulting in more people presenting 
with negative health outcomes. In addition, changes to drug 
policies towards more permissive or punitive approaches and 
an improvement in the level of reporting and monitoring are 
cited as potential reasons for the rise in the number of first-
time cannabis treatment entrants. 
Cannabis use continued
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Figure 1: The number of first-time cannabis treatment admissions 
per year in Ireland, 2003 —2014
Source: National Drug Treatment Reporting System
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17 Importation of drugs
Essentially, between 2003 and 2016 an increase/decrease 
trend has been evident for recorded importation of drugs 
incidents. Increases were seen between 2005 and 2008 
(86%), 2010 and 2011 (41%), 2012 and 2013 (47%), and 2015 
and 2016 (40%). Decreases were seen from 2008 to 2010 
(-57%), 2011 to 2012 (-27%), and 2013 to 2015 (-55%). 
Cultivation or manufacture of drugs
Recorded incidents for the cultivation or manufacture of 
drugs increased between 2003 and 2011. The increase each 
year between 2006 and 2010 was substantial. Between 2011 
and 2015, there was a steady decline in the number of such 
incidents reported; 2015 figures were nearly 60% lower than 
2011. Between 2015 and 2016, recorded incidents increased 
by 10% (see Figure 2).
 
Possession of drugs
Figure 3 shows the number of recorded incidents for 
possession of drugs for sale or supply and for personal use.
Sale or supply
Although the number of recorded offences for possession of 
drugs for sale or supply increased between 2004 and 2008, a 
steady decline was seen between 2008 and 2013. Since 2013, 
the number of incidents recorded increased by 10% in 2014, 
decreased in 2015 (6%), and increased again in 2016 (9%). 
Personal use
The number of incidents recorded for possession of drugs 
for personal use increased between 2003 and 2008. A 
decreasing trend was seen between 2008 and 2013. Since 
2013, incidents recorded for possession of drugs increased 
in 2014 (<1%, 85), decreased in 2015 (3%, 317) and increased 
again by 5% (530) in 2016 (see Figure 3).
Trends in recorded 
drug law offences 
2003—2016
This article examines trends in drug law offences between 
2003 and 2016. Crime data, which are collated on the PULSE 
system by An Garda Síochána, are provided to the Central 
Statistics Office (CSO) for analysis. An incident may consist 
of more than one criminal offence. A primary offence or 
detection may refer to one offence within an incident. 
Sometimes, a charged offence may be different from the 
offence originally identified in the incident. Nevertheless, 
incidents are a useful indicator of the level of particular 
types of criminal activities.1 Figure 1 shows the available 
statistics for recorded incidents of drug offences between 
2003 and 2016, as entered on the PULSE system by Gardaí.
Recorded incidents of drug offences 
Figure 1 provides a summary of the total number of controlled 
drug offences recorded by Gardaí. Following a decline 
between 2008 and 2013, the total number of controlled drug 
offences recorded in Ireland increased in 2014 (4%). Although 
a decline of 5% (15,915 to 15,090) was recorded between 2014 
and 2015, the number of offences recorded increased by 7% 
between 2015 and 2016.2 Further insight can be obtained by 
examining recorded incidents for supply (importation and 
cultivation/manufacture of drugs) and possession (sale or 
supply or personal use) offences separately.
Supply
Figure 2 shows a breakdown of the number of controlled 
drug offences by importation or by cultivation or 
manufacture of drugs recorded between 2003 and 2016. 
Figure 1: Recorded total number of controlled drug offences 
between 2003 and 2016 
Source: Central Statistics Office website (www.cso.ie)
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Figure 2: Recorded incidents of controlled drug offences 
categorised by importation of drugs and by cultivation or 
manufacture of drugs, 2003—2016
Source: Central Statistics Office website (www.cso.ie)
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Other drug offences
The category ‘possession/supply drug offences,  
drug-related crime’ also has a classification for other drug 
offences, which includes forged or altered prescription/
obstruction offences. 
Forged or altered prescription/obstruction under the  
Misuse of Drugs Acts 1977—2016
Although a substantial decrease (28%) was shown in this 
category between 2014 (681) and 2015 (494), crimes recorded 
increased by 24% (157) to 651 in 2016 (see Figure 4).
Driving under the influence of drugs
Driving under the influence of drugs has been a statutory 
offence in Ireland since the enactment of the Road Traffic 
Act 1961.3 A decreasing trend for this offence has been 
evident since 2009, and continued in 2016 (see Figure 4).2
Detected drug offences 2010 and 2014
Court proceedings statistics shed light on the level of 
recorded incidents that become detected crimes, i.e. a 
crime that has been solved by An Garda Síochána. The most 
recent available data are for 2010 to 2014 (see Figure 5). The 
number of offences detected decreased between 2010 and 
2013 by 23%. Between 2013 and 2014, detections increased 
slightly by just over 3%. Notably, an examination by region 
indicates that, although detected offences are dispersed 
throughout the island of Ireland, the majority of detections 
(45%) occur in the Dublin Metropolitan Region followed by 
the Southern Region (17%) representing Cork City, Cork 
North, Cork West, Kerry, Limerick (see Figure 6). 
Ciara H Guiney
1 Central Statistics Office (2014) Interpreting crime statistics: 
a background briefing note. http://www.drugsandalcohol.
ie/24806/
2 Central Statistics Office (2017) Crime and justice statistics. 
Available online at http://cso.ie/en/statistics/crimeandjustice/ 
3 Road Traffic Act 1961. Available online at http://www.
irishstatutebook.ie/eli/1961/act/24/enacted/en/html
Figure 3: Recorded incidents of controlled drug offences 
categorised by possession for sale or supply or for personal use
Source: Central Statistics Office website (www.cso.ie)
Figure 4: Recorded incidents of other drug offences* and  
driving under the influence of drugs, 2003—2016
Source: Central Statistics Office website (www.cso.ie)
*Other drug offences include forged or altered prescription offences and 
obstruction under the Misuse of Drugs Acts 1977—2016
Drug law offences 2003—2016 
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Figure 5: Detected drug offences for Ireland, 2010—2014
Source: Central Statistics Office (2017), unpublished data
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17 • Prevalence rates suggest that there are 18,000 to 23,000 
heroin users in the ROI; the vast majority are thought to 
reside in Dublin. Although heroin seizures increased between 
2014 and 2015 and between 2015 and 2016 in NI, the 
amounts were small. However, due to concerns within the 
community and with the aim of protecting the public at large, 
PSNI investigations are ongoing.
• Cocaine markets in the ROI have been declining since 2007, 
mainly because of the poor economic climate. However, the 
value of cocaine seizures nearly doubled between 2013 (€3.6 
million) and 2014 (€7.5 million). In NI, seizures in 2015/2016 
were lower than the previous year mainly as a result of a 
large 50 kg seizure, which occurred in late 2014.
• Crack cocaine is the drug of choice for individuals whose 
primary addiction is heroin. As a result, its use is not 
widespread. No cases have been reported in NI.
• More recently, NPS have emerged as being seriously 
problematic North and South. A survey carried out by the 
European Commission indicated that 16% of young people in 
the ROI have tried NPS.2 Some 443 NPS are currently being 
monitored by the EMCDDA.
• Although methamphetamine has been low in the ROI for 
the last decade, in the last two years, four ‘box labs’ that 
produce methamphetamine (p. 11) were found in Cork (1), 
Kerry (1) and Dublin (2).
• Producing tablets from pharmaceutical drugs, for example, 
zopiclone, zolpidem or benzodiazepine powders, involves 
ROI OCGs. Prescription drugs, such as alprazolam, 
diazepam and flurazepam, were available illegally and were 
widespread throughout the ROI. Similarly in NI, prescription 
drugs, in particular diazepam, are three times more likely 
to be identified as cause of death than heroin, cocaine, 
amphetamines and mephedrone altogether.
Cross-border activity
The PSNI and AGS are aware of the cross-border links between 
OCGs North and South of the border, in particular for drug-
related crimes. For example:
• Cannabis, cocaine and heroin are imported from the ROI to 
NI by OCGs.
• OCGs on both sides of the border collaborate to import 
drugs from Europe.
• OCGs in NI have links with OCGs in cities in the ROI.
• Drugs are brought to NI via cars, motorcycles, vans, lorries, 
taxis, trains and buses.
• The ROI is used as a transit route by OCGs based in NI, where 
drugs are imported via ports and then transported to NI to 
be distributed or sold.
With the aim of targeting drug-related crime, joint collaborations 
are carried out between the PSNI and AGS. For example, in 
January 2016, the PSNI detained two men in Belfast during the 
handover of herbal cannabis valued at £1 million. In a subsequent 
home search in Drogheda, cannabis and cocaine were recovered 
(estimated value £63,000). 
In another joint operation between the AGS and PSNI, 
codenamed Operation Solaro, cannabis plants were recovered 
from five locations in NI (estimated value £3m) and in County 
Meath (estimated value €750). Arrests were made by the PSNI 
in NI and the AGS in County Meath, numbering 10 and three, 
respectively. Most of the suspects were detained on drug 
trafficking offences.
Ciara H Guiney
Cross-border 
organised crime: threat 
assessment 2016
In September 2016, An Garda Síochána (AGS) and the Police 
Service of Northern Ireland (PSNI) published their biannual 
cross-border organised crime threat assessment.1 The aim 
of the report was to provide insight into how criminal activity 
orchestrated by organised crime groups (OCGs), North and 
South of the border, is disrupted by the work of the Cross 
Border Joint Agency Task Force (CBJATF). The CBJATF involves 
interagency engagement between the PSNI, AGS, Revenue, HM 
Revenue & Customs and other agencies, such as the National 
Crime Agency and the Criminal Assets Bureau. 
Abuse of common travel area
A common travel area (CTA), which has existed between the 
Republic of Ireland (ROI) and the United Kingdom (UK) since the 
1920s, allows for the free movement of goods, money, people 
and information. Despite the many positive aspects of a CTA, 
the land border (approx. 224 miles) that occurs between the 
ROI and Northern Ireland (NI) can leave the CTA exposed to 
abuse from criminals, such as OCGs, who view the setting as 
a way to undertake a wide range of criminal behaviour, for 
example, the smuggling of various illicit commodities including 
drugs, fuel, firearms, counterfeit and contraband cigarettes 
and alcohol (p. 6). 
Organised crime groups
Investigations into OCGs on both sides of the border have 
demonstrated that links and communication between groups 
are strong. Indeed, intel on mobile OCGs, which focuses on 
cross-border activity, suggests that OCGs from the South travel 
into the North to carry out crimes and vice versa. Notably, these 
offenders willingly resort to violence; in consequence, victims 
and police personnel are at risk. The majority of cross-border 
links are for drug-related activities, for example, trafficking and 
the cultivation and importation of heroin, cocaine and cannabis. 
To ensure criminality succeeds, OCGs have established ‘mutually 
beneficial business relationships’ throughout each area (p. 7). 
Foreign national OCGs, originating from South East Asia, Africa, 
Portugal, Spain, Italy, Russia, Lithuania, Albania, Romania and 
elsewhere in Europe, have become more prominent in NI. These 
groups also undertake criminal behaviour in the South. It is 
alleged that key members are located in the ROI and repeatedly 
obtain money from criminal activities undertaken in NI. In 
addition, paramilitary groups involved in organised crime also 
operate North and South of the border.
Cross-border organised crime: drugs
The report highlights that drugs and drug-related criminality is 
a ‘common concern’ in NI and the ROI. During the last number 
of years, the drug market has become more varied. ‘Traditional’ 
drugs remain prominent (p. 8); however, new psychoactive 
substances (NPS) are on the rise. The main source of income for 
OCGs throughout the island is from ‘traditional’ drugs, and how 
these products are imported and dispersed remains unchanged. 
For example:
• Cannabis is the most widespread drug in the ROI and NI. Data 
from drug treatment centres, in both regions, indicate that 
treatment referrals for cannabis are higher than for other 
drug types.
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1 Police Service of Northern Ireland and An Garda Síochána (2014) 
Cross border organised crime: threat assessment 2016. Belfast 
and Dublin: Department of Justice (UK) and Department of Justice 
and Equality (ROI). Available online at http://www.octf.gov.uk/
Publications/SARS-information-(1)/Cross-Border-Organised-
Crime-Assessment-2016 
2 Gallup Organization and European Commission (2011) Youth 
attitudes on drugs: analytical report – Flash Eurobarometer  
330. Brussels: European Commission. Available online at  
http://ec.europa.eu/commfrontoffice/publicopinion/flash/
fl_330_en.pdf 
Injecting drug use 
and hepatitis C 
treatment 
People who inject drugs (PWID) represent the majority of the 
hepatitis C virus (HCV) epidemic in the developed world.1 The 
majority of new infections develop in active PWID, with this 
group accounting for more than 80% of new infections in high-
income countries.2 Furthermore, an additional large reservoir of 
infection exists among former PWID who remain undiagnosed.
Historically, HCV treatment guidelines have excluded PWID from 
consideration for treatment. Drug injectors are viewed as having 
‘difficult to treat’ HCV disease, with perceived inferior treatment 
adherence and outcomes, and concerns regarding reinfection 
risk. Important factors that have limited treatment uptake in 
PWID are the contraindications and adverse effects of interferon 
(IFN) based therapy. The development and availability of IFN-free 
direct acting antiviral (DAA) regimes with high efficacy, improved 
tolerability and a limited side-effect profile will significantly 
increase the proportion of patients who can be offered 
HCV therapy. However, adherence to therapy in ‘real world’ 
population groups will remain paramount in the DAA era. 
A recent study conducted in Ireland investigated differences in 
HCV treatment adherence and outcomes between former PWID, 
recent PWID, and non-drug users treated with IFN and ribavirin 
therapy.3 In this study, published in the journal PLOS ONE, 
differences between PWID and non-drug users were analysed  
for adherence to treatment and outcomes in all patients treated 
for chronic HCV infection in a university teaching hospital from 
2002 to 2012. The PWID group also included former and recent 
drug users who were treated in a community-based drug 
treatment centre. 
Results  
Treatment completion/compliance
There were 608 former PWID, 85 recent PWID, and 307 non-
PWIDs who commenced HCV therapy. There was no significant 
difference in treatment non-completion (for reasons other than 
virologic non-response) between PWID and non-PWIDs (8.4% vs 
6.8%, relative risk: 1.23, 95% CI: 0.76–1.99). Additionally, there 
was no significant difference in treatment non-completion 
between former and recent PWID (8.7% vs 5.9%, relative risk: 
0.84, 95% CI: 0.33–2.10). Fifteen patients (17.6%) in the recent 
PWID group tested positive for opiates at least once during 
treatment, 11 (12.9%) tested positive for benzodiazepines, and 
5 (5.8%) tested positive for cocaine. Seven patients tested 
positive for two of the drug classes, while 5 tested positive for all 
three classes. No patients reported injecting illicit drugs during 
treatment or in the 6-month post-treatment follow-up period.
Response to treatment
As shown in Figure 1, the overall sustained virologic response 
(SVR) rate in PWID (64.1%) was not different from non-PWIDs 
(60.9%) (relative risk: 1.05, 95% CI: 0.95–1.17). In addition, there 
was no significant difference in SVR rates between the groups 
when comparing genotype (GT) 1 and genotype 3 infections.
Follow-up data on 219 former PWID who achieved SVR between 
2002 and 2007 for a median of 57 months (range 6–168 
months) indicated that 13 patients were reinfected with HCV, 
a reinfection rate of 10.5/1000 person years of follow-up. All 
13 patients had a relapse in injecting drug use. There was no 
significant difference in reinfection rate between former PWID 
with and without HIV co-infection.
Conclusions
The results from this large retrospective study of a decade 
of HCV treatment outcomes indicate that PWID have similar 
treatment adherence to IFN and DAA HCV therapy as non-
PWID patients with chronic HCV infection. In addition, PWID 
patients have a comparable response to treatment. The authors 
concluded that prioritising PWID for HCV treatment may be a 
more cost-effective initiative for reducing long-term health 
costs and that HCV elimination is an ambitious target that cannot 
be achieved by excluding PWID from treatment.
Seán Millar
1 Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak 
D and Degenhardt L (2011) Global epidemiology of hepatitis B 
and hepatitis C in people who inject drugs: results of systematic 
reviews. Lancet, 378: 571—83.
2 Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, et al. (2011) 
A systematic review of hepatitis C virus epidemiology in Europe, 
Canada and Israel. Liver International, 31: 30—60.
3 Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C and Norris 
S (2017) Outcomes from a large 10 year hepatitis C treatment 
programme in people who inject drugs: no effect of recent or 
former injecting drug use on treatment adherence or therapeutic 
response. PLOS ONE, 12(6): e0178398.
Figure 1: Treatment response. Rates of sustained virologic  
response (95% CI bars) with dual therapy in PWID and non-PWID 
(a) for all genotypes: 64.1% vs 60.9% (b) genotype 1: 48.6% vs 
48.6% and (c) genotype 3: 74.7% vs 73.3%
Source: PLOS ONE, 2017
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17 Trends in alcohol, 
tobacco and cannabis 
use among school-
aged children in 
Ireland, 1998—2014 
The first Health Behaviour in School-Aged Children (HBSC) 
survey was conducted in Ireland in 1998 and has been 
repeated every four years since then. In 2014, the study was 
conducted in Ireland for the fifth time. This survey included 
13,611 children drawn from 3rd class in primary school 
through to 5th year in post-primary school; 230 primary and 
post-primary schools across Ireland participated. Data were 
collected on general health, social class, smoking, use of 
alcohol and other substances, food and dietary behaviour, 
exercise and physical activity, self-care, injuries, bullying and 
sexual health behaviours. This article presents findings from 
a 2017 report which examined trends in alcohol, tobacco and 
cannabis use among 10—17-year-old children between 1998 
and 2014.1
Alcohol use
Children were asked if they had ever had so much alcohol 
that they were really drunk. The response options ranged 
from ‘never’ to ‘yes, more than 10 times’. Findings indicated 
that there has been a statistically significant decrease in the 
proportion of children who reported having ever been drunk 
between 1998 and 2014 (Figure 1). Statistically significant 
decreases in the proportion of those who had ever been drunk 
were observed in boys and girls and in children from all age 
groups, and all social class groups, over time. Overall, 58.2%, 
57.2%, 52.7% and 41.2% of 15—17-year-olds reported having 
ever been drunk in 2002, 2006, 2010 and 2014, respectively. 
Of those who had ever been drunk, there was a statistically 
significant decrease between 2002 and 2014 in the proportion 
of 15—17-year-old boys and girls who reported having their first 
alcoholic drink aged <11, <13 and <15 years.
Figure 1: Percentage of 10 —17-year-olds who reported having ever been drunk, overall and by gender from 1998 to 2014 
Source: HBSC Ireland, 2017
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Figure 2: Percentage of 10—17-year-olds who reported being a current smoker, overall and by gender from 1998 to 2014 
Source: HBSC Ireland, 2017
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Tobacco use
Children were asked how often they smoke at present. The 
response options ranged from ‘I do not smoke’ to ‘every 
day’. Current smoking as presented below is defined as 
smoking monthly or more frequently. Between 1998 and 
2014, there was a statistically significant decrease in the 
proportion of children who reported being a current smoker 
(Figure 2). Compared to 1998, significantly fewer boys and 
girls reported being a current smoker in 2014. Over time, 
statistically significant decreases in the proportion of current 
smokers were apparent in all age and social class groups. 
Overall, 61.7%, 54.2%, 46.1% and 27.5% of 15—17-year-olds 
reported ever having smoked in 2002, 2006, 2010 and 2014, 
respectively. Of those who had ever smoked, there was a 
statistically significant decrease between 2002 and 2014 
in the proportion of 15—17-year-old boys and girls who 
reported having smoked their first cigarette aged <11, <13  
and <15 years.
Cannabis use in the last 12 months
Children were asked if they had used cannabis in the last 12 
months. The response options ranged from ‘never’ to ‘40 
times or more’. The findings below present the proportion 
of children who reported cannabis use in the last 12 
months. Between 1998 and 2014, there was a statistically 
significant decrease in the proportion of children who 
reported using cannabis (Figure 3). Statistically significant 
decreases in the proportion of children who reported 
cannabis use over time were apparent in the majority of the 
age and social class groups.
International ranking (15-year-olds)
In 2014, 15-year-olds in Ireland were below the international 
HBSC average for being a current smoker (Ireland 10.8%; 
HBSC average 17.1%). Ireland ranked 12th in 1998, 20th in 
2002, 13th in 2006, 23rd in 2010 and 25th in 2014. With 
regard to children reporting ever having been drunk, 
15-year-olds in Ireland were below the international HBSC 
average for this indicator (Ireland 27.0%; HBSC average 
37.6%). Ireland ranked 18th in 1998, 21st in 2002, 17th in 
2006, 17th in 2010 and 21st in 2014. No internationally 
comparable data were available regarding cannabis use.
Conclusions
In summary, results from the HBSC surveys suggest a decline 
in the use of alcohol, cigarettes and cannabis among school-
aged children in the Republic of Ireland. In a commentary 
on the report, the Minister of State for Health Promotion 
at the Department of Health, Marcella Corcoran Kennedy 
TD, noted that the HBSC surveys provide policy-makers 
and researchers with access to key data to inform policy 
and service development. The data are also a key factor in 
designing policy for the prevention of poor health behaviours 
and for the promotion of healthy ones.
Seán Millar
1 Keane E, Gavin A, Perry C, Molcho M, Kelly C and Nic Gabhainn 
S (2017) Trends in health behaviours, health outcomes and 
contextual factors between 1998—2014: findings from the 
Irish health behaviour in school-aged children study. Dublin: 
Department of Health and National University of Ireland Galway. 
http://www.drugsandalcohol.ie/27365/ 
Figure 3: Percentage of 10—17-year-olds who reported using cannabis in the last 12 months, overall and by gender from 1998 to 2014 
Source: HBSC Ireland, 2017
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use among OST 
patients
According to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) annual report for 2017 on estimates 
of drug use in the European Union (EU),1 cocaine is the most 
commonly used illicit stimulant drug in Europe. It is estimated 
that 17.5 million European adults (aged 15—64 years), or 5.2% of 
this age group, have experimented with cocaine at some time 
in their lives. Among these are about 2.3 million young adults 
aged 15 to 34 years (1.9% of this age group) who have used the 
drug in the last year. Only Ireland, Spain, the Netherlands and 
the United Kingdom (UK) report last-year prevalence of cocaine 
use among young adults of 2.5% or more.1 The 2014/15 general 
population survey reported that 2.9% of young Irish adults 
had used cocaine in the last year.2 Around one million seizures 
of illicit drugs are reported annually in Europe. Cocaine is the 
second most commonly seized drug (after cannabis). In total, 
around 87,000 seizures of cocaine were reported in the EU in 
2015. Both the number of cocaine seizures and the quantity 
seized increased between 2014 and 2015 in Europe.1
Cocaine use in Ireland
In Ireland, in 2015, drug seizures conducted by An Garda 
Síochána alone included 108,817 grams of cocaine at an 
estimated street value of €7,617,223.3 Increased seizures of 
cocaine have been reported by Forensic Science Ireland.4 
Information on the strength of cocaine currently in 
circulation in Ireland is not known. However, in 2015, Forensic 
Science Ireland reported that the average purity of 158 bulk 
cocaine samples analysed was 40% (range 0.03—91%), while 
that of 36 street cocaine samples analysed was 24% (range 
0.1—78%); 21 from Dublin (average 28%) and 15 from outside 
Dublin (average 19%).4 
The National Drug Treatment Reporting System (NDTRS) 
recorded cases of treated problem drug and alcohol use in 
Ireland between 2009 and 2015. Cocaine remains the third 
most common drug reported. In 2015, 10.4% of cases reported 
problem cocaine use, the highest proportion since 2010.5 
European drug data
European Drug Emergencies Network (Euro-DEN Plus) 
monitored 5,054 drug-related hospital emergency 
presentations in 15 sentinel hospitals in nine European 
countries over a 12-month period (October 2013—September 
2014), including two Irish hospitals. These were Our Lady of 
Lourdes Hospital, Drogheda and the Mater Misericordiae 
University Hospital, Dublin. Presentations had a median age 
of 31 years, and most were male (77%). On average, about 
1.5 drugs were reported per presentation. Cocaine was the 
second most common drug involved in presentations overall; 
in the Mater Misericordiae University Hospital, cocaine was 
involved in 102 (19.4%) of presentations, second only to 
heroin at 154 (29.3%) of presentations.6
Drug use is a recognised cause of avoidable mortality 
among European adults. Ireland has the fourth highest drug 
overdose death rate in Europe (71 per million).1 Poisoning 
deaths in Ireland where cocaine was implicated decreased 
over the years of economic recession from a high of 65 
in 2007 to 21 in 2010. However, since 2010, the number of 
deaths where cocaine was implicated have been increasing 
again. There was a 25% increase from 32 deaths in 2013 to 
40 deaths in 2014 (NDRDI data) (Figure 1).7
National Drug Treatment Centre drug testing
The Health Service Executive (HSE) National Drug Treatment 
Centre (NDTC) laboratory provides a national service to the 
HSE Addiction Services, hospitals, general practitioners, 
voluntary organisations, juvenile detention centres), the 
Probation Service, and the Courts Service. The laboratory is 
accredited by the Irish National Accreditation Board (INAB) 
to ISO/IEC 17025 standard (INAB scope 169T). The majority 
of the testing carried out is for patients who are on opioid 
substitution treatment (OST). Because of the large sample 
throughput per annum, the NDTC laboratory is ideally 
placed to monitor trends in the prevalence of drug use in 
the addiction population. The percentage of samples testing 
positive for drugs of abuse may be used as a quantitative 
measure of the extent of their use. 
The number of samples positive for cocaine were high in 
this cohort during the years 2004–2009 (which roughly 
correspond to the Celtic Tiger years), but decreased 
between 2008 and 2012, from 9.6% to 4.9%, respectively, 
which again could be attributed to the recession years. 
Figure 1: Number of poisoning deaths where cocaine was implicated, NDRDI 2004—2014 
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However, since 2012, there has been year-on-year increases 
in the numbers of samples testing positive for cocaine 
(Figure 2). 
A degree of correlation between the number of deaths 
where cocaine was implicated and patient samples testing 
positive for cocaine seems evident (as would be expected). 
With increased cocaine usage in 2015 and 2016, one might 
anticipate increased deaths involving cocaine in these 
years (figures not yet available) and further increases into 
the future, as cocaine positive samples are continuing to 
increase month by month (Figure 3). In June 2017, 13.2% of 
all samples tested positive for cocaine. This is significantly 
higher than what was seen at the height of the Celtic Tiger 
from 2004 to 2008 and the ongoing trajectory appears to 
be upwards.
It should be noted that these percentages represent the 
average positive samples over all of the patients and include 
patients in abstinence programmes. While the average in 
June 2017 reached a high of 13.2%, further breakdown of the 
data shows that there are significant regional variations, with 
the use of cocaine being much greater in Dublin. Positive 
samples over Dublin OST clinics in June 2017 averaged 17.6%, 
with one clinic as high as 34%. The routine testing used does 
not distinguish between cocaine powder and crack cocaine.
In Europe overall, reflecting the ageing nature of its opioid-
using population who are at greatest risk of drug overdose 
death, overdose mortality rates peak at age 35—39 years for 
males and age 30—34 years for females. While the NDTRS 
data7 show that the median age of cases in treatment for 
problem drug use (excluding alcohol) increased from 28 years 
in 2009 to 30 years in 2015, the median age for this group 
who tested positive for cocaine was 38 years. 
Figure 3: NDTC laboratory monthly cocaine average positive samples, January 2013—June 2017 
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Figure 4: Age profile of patients testing positive for cocaine, April 2017
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Eleven (1.2%) patients were aged 16—19 years; 26 (2.7%)  
were aged 20—24; 73 (7.7%) were aged 25—29; 165 (17.3%) 
were aged 30—34; 126 (28.8%) were aged 35—39; 237 
(24.8%) were aged 40—44; 118 (12.4%) were aged 45—49; 46 
(4.8%) were aged 50—54; 15 (1.6%) were aged 55—59; and 7 
(0.7) were over 60 (Figure 4). 
Of 954 patients who tested positive for cocaine in the NDTC 
laboratory in April 2017, 71% were male and 29% female.
Discussion
It is evident that cocaine use is increasing again among this 
vulnerable cohort. With increased numbers of patients 
attending OST also using cocaine, treatment needs to be 
adapted to address the different challenges presented and 
to try to reduce the ongoing death toll from cocaine. The 
general public should also be made aware of the very real 
risk of fatality from cocaine use.
Siobhan Stokes
1 European Monitoring Centre for Drugs and Drug Addiction 
(2017) European drug report 2017: trends and developments. 
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/27401/ 
2 National Advisory Committee on Drugs and Alcohol (NACDA)  
and Department of Health (UK) (2016) Prevalence of drug use 
and gambling in Ireland and drug use in Northern Ireland. 
Bulletin 1. Dublin: NACDA and Department of Health (UK).  
http://www.drugsandalcohol.ie/26364/
3 An Garda Síochána (2016) Annual report of An Garda Síochána 
2015. Dublin: An Garda Síochána. http://www.drugsandalcohol.
ie/26524/ 
4 O’Neill G, Clinton D and Lynch B (2015) Purity of illicit drugs 
submitted to Forensic Science Ireland 2015. Dublin: Forensic 
Science Ireland. http://www.drugsandalcohol.ie/26311/ 
5 Health Research Board (2017) Drug treatment in Ireland:  
NDTRS 2009—2015. Dublin: Health Research Board.  
http://www.www.drugsandalcohol.ie/27023/ 
6 European Drug Emergencies Network (2015) Final report of the 
European Drug Emergencies Network (Euro‐DEN). Available 
online at http://www.emcdda.europa.eu/attachements.cfm/
att_250356_EN_Euro_DEN%20final%20report%202015.pdf 
7 Health Research Board (2016) National Drug-Related Deaths 
Index 2004 to 2014 data. Dublin: Health Research Board.  
http://www.www.drugsandalcohol.ie/26299/ 
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RESPONSES 
SAOR: Screening and 
brief intervention for 
problem alcohol and 
drug use 
The Health Service Executive (HSE) has published the second 
edition of the SAOR (Screening and Brief Intervention 
for Problem Alcohol Use) model first introduced in 2009. 
Developed by O’Shea, Goff and Armstrong, SAOR II provides 
an evidence-based framework for screening and brief 
intervention (SBI) for problem substance use for application 
in a range of settings and with all levels of need.1 The 
document provides a step-by-step guide as well as outlining 
the context, rationale and evidence underpinning the model.
Background and context
Originally, the SAOR model was developed for the delivery 
of brief interventions for problem alcohol use in emergency 
departments and acute settings. SAOR II expands the 
model by making it applicable in a broader range of health, 
social care, social and recreational settings and for other 
substances in addition to alcohol.
SAOR II is underpinned by a biopsychosocial model, which 
understands problem substance use as the complex 
interaction of the individual, social and family factors, and 
substance-related characteristics. From this perspective, an 
effective response to problem substance use must involve 
a range of different interventions that are readily available 
to individuals depending on their needs and circumstances. 
SBI is one of a continuum of supports that may be offered. 
SBI aims to enhance an individual’s motivation to change 
substance-using behaviour. The more SBIs experienced, the 
greater the potential impact on a person’s motivation to 
change. SBI enables early intervention with at-risk groups 
in a variety of settings and referral onwards to specialised 
services as appropriate. A body of literature supports the 
use of SBI with those with low-to-medium alcohol problems 
as well as those with drug/alcohol dependence, and suggests 
it may also be valuable as part of a range of interventions for 
those receiving opiate substitution. 
The use of SBI as part of a continuum of interventions 
reflects international and national policy and guidelines 
addressing problem drug and alcohol use. In Ireland, 
priorities of the National Drug Rehabilitation Framework 
(NDRF)2 and National Drugs Strategy (NDS) 2017—2015,3 
which reflect the Four-Tier Model of Care,4 include ensuring 
that people with substance use problems can access the 
necessary supports close to home and at a level appropriate 
to their needs. Action 2.1.26 of the NDS 2017—2025 
emphasises training in the delivery of SBI and onward referral 
to ensure early intervention for at-risk groups.
SAOR II screening and brief intervention 
SAOR II is underpinned by a person-centred approach, 
recognising the power of the therapeutic relationship and 
the individual’s capacity to make positive behaviour changes. 
It reflects the principles of respect, care and compassion, 
and acknowledges the person’s autonomy in decision making. 
New to SAOR II is an emphasis on aspects of motivational 
interviewing (MI),5 which is used to express the person-
centred approach. MI is ‘a form of collaborative conversation 
which strengthens a person’s own internal motivation and 
commitment to change’ (p. 39).1 
The four processes of MI (engaging, focusing, evoking, and 
planning) are reflected in the four stages of SAOR II: 
1    Establishing a supportive relationship through listening and 
making the person feel comfortable.
2  Asking questions to determine the existence and extent of 
a problem. 
3  Offering assistance, guidance or advice.
4  Referring on to other specialised services as appropriate. 
Using MI techniques, SBI can be provided in an extended 
form (20—30 minute interventions), allowing for a more 
extensive interaction for those with more complex needs. 
SAOR II can be used in any setting in the treatment 
continuum, regardless of the level at which care is provided.
SAOR training
Since 2012, a one-day training programme in SAOR SBI has 
been provided by the National SBI Project for Problem 
Alcohol and Substance Use in partnership with the National 
Addiction Training Programme. A SAOR Train the Trainer 
programme has also been rolled out. An eLearning resource 
based on the SAOR model was developed in 2017 and has 
enabled the model to have greater reach. A suite of SBI 
online training resources based on SAOR II is being prepared 
through the National Office for Social Inclusion and Ana 
Liffey Drug Project and will be available to support the 
delivery of training and implementation of SBI.
SAOR II is an evidence-based psychosocial intervention that 
aims to effect behavioural change in persons experiencing 
problem substance use. As an SBI, SAOR II can be one of a 
comprehensive set of supports that together address the 
context, causes and maintenance of problem substance use. 
SAOR II can be delivered in multiple settings and with a range 
of substances and levels of need. 
Cathy Kelleher
1 O’Shea J, Goff P and Armstrong R (2017) SAOR: Screening and 
brief intervention for problem alcohol and drug use. 2nd edn. 
Dublin: Health Service Executive. http://www.drugsandalcohol.
ie/27443/ 
2  Doyle J and Ivanovic J (2010) National drugs rehabilitation 
framework document. National Drugs Rehabilitation 
Implementation Committee. Dublin: Health Service Executive. 
http://www.drugsandalcohol.ie/13502/ 
3  Department of Health (2017) Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in 
Ireland 2017—2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/ 
4  For further details, see Reducing harm, supporting recovery 
(2017, p. 33).
5  Miller WR and Rollnick S (2013) Motivational interviewing: 
helping people change. 3rd edn. New York: Guilford Press. 
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17 It was not possible to determine how many doctors or 
treatment centres participated, as the study was anonymous. 
The main findings from this audit are outlined below.
Findings 
Age and sex 
Where data were available, 63% (198/315) of the population 
were male and the age range was 24—65 years. The median 
age for males was 38 years, while the median age for females 
was 36 years. The majority of patients (81%) were between 
the ages of 25 and 44 years.
Risk factors for HCV infection
Information on possible risk factors for infection was 
available for 65% (208/319) of patients (Figure 1). Of these 
patients, 85.1% (177/208) had a history of injecting drug 
use (people who inject drugs — PWID), 10.6% (22/208) had 
non-injecting drug use risk factors and 4.3% (9/208) had no 
known risk factor. Of those with non-injecting drug use risk 
factors, 17 reported cocaine use, 4 reported unprotected 
sex with a HCV positive person, and 1 reported both cocaine 
use and unprotected sex with an HCV positive person.
Of the 177 patients who had a history of injecting drug use, 
72% (128) were HCV antibody positive and 44% (78) were HCV 
antigen or polymerase chain reaction (PCR) positive. In those 
with HCV antigen or PCR positive results, the age range was 
24—56 years, with a median age of 40 years. The likelihood 
of having HCV increased with age in those with a history 
of injecting drug use, with 63% (10/16) of 25—34-year-
olds testing positive for HCV antigen or PCR compared 
to 68% (45/66) of 35—44-year-olds and 80% (20/25) of 
45—54-year-olds. Data on HCV testing were available for 14 
patients, of whom 5 were positive for HCV antibodies. Two of 
these 5 patients were also HCV antigen or PCR positive. 
HIV infection 
HIV status was recorded on 242 patients, of whom 39 (16%) 
were HIV positive. The median age of HIV positive patients 
was 39 years (range 31—56 years). Of these, 37 were also 
HCV antibody positive; 20 of these were HCV antigen or PCR 
positive. The majority (70%) of those co-infected with HIV 
were male. Where data were available, 97% (34/35) of all HIV 
positive patients were reported to have a history of injecting 
drug use. Overall, 19% (34/177) of those with a history of 
injecting drug use were HIV positive.
Audit of hepatitis C 
testing and referral, 
2015 
In 2014/15, an audit was carried out in Ireland of hepatitis 
C (HCV) testing and referral in Addiction Treatment Centres 
in Health Service Executive (HSE) Community Health 
Organisation (CHO) Area 7 (formerly HSE Dublin Mid-
Leinster). CHO Area 7 covers Dublin 2, 4 (part of), 6, 6W, 
8, 10, 12, 16 (part of), 22 and 24. The audit was not carried 
out in the satellite clinics or in West Wicklow and Kildare as 
services there are in community-based general practice. 
The number of patients attending the addiction treatment 
centres in CHO 7 at the time of starting the audit was 1,255. 
The purpose of this audit was to inform the Audit Sub-Group 
of the Addiction Treatment Clinical Governance Committee 
of CHO 7 of compliance with the expected standard of 
care in relation to HCV, and to make recommendations for 
improvement where necessary. A secondary aim of the study 
was to collect and collate data on the prevalence of HCV 
infection in this sample of patients.1
Methods 
A customised audit form was developed. One form was to 
be completed for each patient attending the centre. Data 
were requested on age, gender, and whether or not the 
patient was tested for HCV. Risk factors for infection, co-
infection with HIV, referral to a specialist clinic (hepatology 
or infectious diseases), attendance at a specialist clinic 
and what level of treatment, if any, was provided were 
also requested. No personally identifiable information was 
collected on patients. In order to encourage cooperation 
and to avoid making comparisons between centres, the  
form did not contain the name of the doctor or the 
treatment centre. 
A letter accompanied by the audit form was sent to 20 GPs 
in 11 addiction treatment centres in CHO 7 outlining the audit 
project and requesting their assistance in completing the 
forms. A total of 319 audit forms were returned, representing 
25% of the patients attending the services at that time. 
Figure 1: Risk factors for HCV infection among patients* in selected addiction treatment centres in Ireland, 2014/15
Source: Health Protection Surveillance Centre, 2017
*Risk factor data available for 65% of patients.
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• A computerised-patient management system for 
addiction treatment clinics is urgently needed. This 
would improve the efficiency of the clinics and make 
better use of staff resources, and would improve quality 
of care for patients.
• The under-resourcing of clinics is an ongoing cause for 
concern and should continue to be highlighted on the 
HSE Risk Register. 
• Improved communication from specialist hospital clinics 
to the referring doctors in the addiction treatment clinics 
regarding patients who have been offered treatment 
would be helpful to patient care. In particular, it would be 
useful for the referring doctor to have timely information 
on uptake of treatment and response to treatment, and 
also to know if the patient has refused treatment. The 
HCV liaison nurses may have a role to play in improving 
this information flow. 
• Individual doctors and clinics should be supported in 
maintaining compliance with HCV testing and referral. 
• Attendance at specialist hepatology and infectious 
diseases clinics, particularly for younger patients, should 
be encouraged by referring doctors and by the HCV 
liaison nurses. The reasons for poor attendance should 
be investigated. 
• Addiction treatment doctors and HCV liaison nurses 
have a role in educating patients about the risks and 
prevention of blood-borne virus transmission, and about 
the availability of new antiviral treatments.
In addition, the authors recommend that the audit should 
be repeated. It was suggested that the next audit should 
explore the practices in relation to retesting those patients 
who initially test HCV negative but have ongoing risk-taking 
behaviour. It should also seek to gather more detailed 
information about treatment uptake and outcome. A repeat 
study would be helpful to indicate if recently observed 
increases in the incidence of HIV infection in drug users has 
been mirrored by a rise in HCV infection. It is hoped that the 
circulation of this report may encourage a better response 
rate for the next audit. A better response would allow for 
more confidence in the representativeness of the findings 
and more clearly indicate opportunities for improvement.
Seán Millar
1 Bourke M, Hennessy S, Thornton L (2015) Audit of hepatitis C 
testing and referral: Addiction Treatment Centres, Community 
Health Organisation Area 7. Lenus, the Irish Health Repository. 
Available online at http://www.drugsandalcohol.ie/28118/ 
2 Health Service Executive (2012) National hepatitis C strategy 
2011—2014. Dublin: Health Service Executive. Available online at 
http://www.drugsandalcohol.ie/18325/
3 HSE — Health Protection Surveillance Centre (2015)  
Annual epidemiological report 2014: hepatitis C. Dublin:  
Health Service Executive. Available online at  
http://www.drugsandalcohol.ie/28119/
 
 
Referral and attendance at hepatology or 
infectious diseases clinics by gender 
Where data were available, 86% (88/102) of HCV antigen or 
PCR positive patients were referred to a specialist clinic and, 
of those, 66% (52/79) attended. Males were more likely than 
females to attend a specialist clinic following referral, with a 
74% (39/53) attendance rate, compared to just 50% (13/26) 
of females. The likelihood of attendance at a specialist clinic 
also increased with age, with just 36% (4/11) of those in the 
25—34-years age group having attended following referral, 
compared to 68% (30/44) of 35—44-year-olds and 76% 
(16/21) of 45—54-year-olds.
Treatment uptake and completion 
Data were collected on whether or not treatment was 
offered, accepted, completed and successful in antigen 
positive patients. Out of 105 patients who tested positive 
for the HCV antigen or PCR, data were available on offer of 
treatment for 57 patients. Of those, 28 patients (49%) were 
recorded as having been offered treatment and 29 were 
not offered treatment. Of the 28 patients who were offered 
treatment, 6 were awaiting treatment at the time of audit, 
3 were still in treatment, 4 had refused treatment, 7 had 
completed treatment and there was no further information 
on the remaining 8 patients. Of the 7 patients who had 
completed their treatment, it was successful in 4, and no 
information was provided on the remaining 3 cases.
Conclusions and recommendations
One aim of this audit was to provide information on the 
current prevalence of HCV infection in patients attending 
addiction treatment clinics in Ireland. Two-thirds (67%) 
of patients who had been tested were positive for HCV 
antibodies. This figure is in keeping with previous studies in 
Ireland among PWID, which found the prevalence to be 62% 
to 81%.2 The prevalence was slightly higher (72%) in those 
with a recent history of injecting drug use. The prevalence 
of HCV markers was higher in older patients, which may 
reflect their longer injecting history and opportunity for 
exposure to HCV, or may indicate a reduction in incidence 
in recent years. 
Data from nationally collated notifications of HCV infection 
show a substantial downward trend in notifications, and 
rising age at diagnosis, since peak levels in 2007.3 However, it 
must be borne in mind that, given the overall low response 
rate to this audit, the findings may not be representative of 
the population of patients attending addiction treatment 
services in this region, or in Ireland. 
The following were among the recommendations suggested 
by the authors to further understand infectious disease 
prevalence among drug users in Ireland:
Audit of hepatitis C testing  
and referral continued
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who had died during the timeframe. 
Prescription refill data were used to assess the level 
of supervised methadone for each treatment episode, 
with those dispensing a single dose categorised as 
supervised. For each patient, the percentage of supervised 
prescriptions was calculated and classified as 20%,  
20—39%, 40—59%, 60—79%, or 80% or more. Prescription 
data were also used to calculate the total number of 
prescriptions (comorbidity score) for other drugs issued to 
each patient across the timeframe. 
Patients were deemed to be in continuous treatment if they 
had received a new prescription within seven days of the 
end of coverage of a prescription, and as ceased treatment 
if they had not. Retention in treatment was designated for 
treatment episodes that had no interruption in prescribed 
methadone lasting more than seven days. The length of 
treatment episodes was based on the date of the first 
prescription and coverage of the last. Only episodes that 
started within the timeframe of interest were included in 
the analyses. 
Statistical analyses examined the relationship between 
supervised methadone consumption and time to 
discontinuation of treatment across multiple treatment 
episodes, accounting for recurrent methadone treatment 
episodes, and including age, gender, median daily methadone 
dose and comorbidities as potential confounders. 
Results
• 36% of patients were supervised for less than 20% of 
prescriptions, 16% for 20—59%, and 48% for 60% or more 
during the initial treatment episode. 
• Across episodes, treatment discontinuation was least 
among patients supervised for 20—59% of prescriptions, 
and was greatest among patients supervised for 60% or 
more (indicating a J-shaped relationship). 
• 67% of patients experienced more than one treatment 
episode; the median episode length for the initial 
treatment episode was 224 days; and the overall median 
episode length was 104 days. 
• Daily methadone doses ranging from 60 to 120 mg per day 
were more effective at retaining patients in treatment than 
doses of less than 60 mg, or greater than 120 mg per day. 
• The minimum recommended daily dose (60 mg) was 
not received by one-third of patients during the initial 
treatment episode. 
• Many patients received co-prescriptions, most commonly 
for benzodiazepines (72%) and antidepressants (49%). 
Those with 11 or more were significantly more likely to have 
shorter treatment episodes than those with five or fewer. 
Discussion 
The J-shaped relationship identified suggests that with too 
little or too much supervision, patients may drop out of 
methadone treatment. This finding is consistent with trials 
in the US and Scotland, and is supported by qualitative 
research suggesting that supervision can be acceptable 
to patients in the short-term, as they develop a routine 
and establish relationships with staff, but that patients 
prefer to be unsupervised in the longer-term. The authors 
propose that other studies that found no differences in 
retention based on whether consumption was supervised or 
Relationship 
between supervised 
methadone 
consumption and  
retention in treatment 
in primary care
A J-shaped relationship between supervised methadone 
consumption and retention in methadone maintenance 
treatment in primary care represents a ‘double edge sword’, 
according to authors of a study recently published in Drug 
and Alcohol Dependence.1 Funded by the Heath Research 
Board (HRB) through the HRB Centre for Primary Care 
Research, the study is the first to examine the influence 
of supervised methadone consumption on retention in 
methadone treatment over multiple treatment episodes in 
primary care. 
Supervised methadone consumption
Supervised methadone consumption entails the 
administration of methadone to patients by a pharmacist 
or clinician, thus ensuring patients take methadone as 
prescribed. Ensuring patient compliance can prevent 
diversion of methadone to illicit drug markets and can 
reduce relapse to heroin use. Research has found supervised 
methadone consumption to be associated with a reduction 
in drug-related deaths, including those attributed to 
methadone. However, long-term supervision is resource 
intensive and may promote dropout from treatment due 
to the disruption to patients’ lives. Conflicting findings 
have emerged from the few studies that have compared 
supervised and unsupervised consumption. 
At the time of the study, and consistent with World Health 
Organization recommendations, Irish guidelines for 
methadone maintenance treatment in primary care advised 
a minimum of one dose per week administered under 
pharmacy supervision.2,3 A dose of 60—120 mg daily, with 
prescriptions issued to dispense methadone for up to seven 
days, was further recommended.
Method
The sample consisted of 6,393 patients who experienced at 
least one methadone treatment episode between 2004 and 
2010, and 19,715 treatment episodes. Patients were mostly 
male (68.5%) and aged under 30 years (58.6%). 
The sample was identified by linking data from the Central 
Treatment List (the national register for methadone 
maintenance treatment); records from the Health Service 
Executive’s Methadone Treatment Scheme; the General 
Medical Services (GMS) pharmacy claims; and the HRB’s 
National Drug-Related Deaths Index (NDRDI). Included were 
persons aged 16—65 years who had at least three methadone 
prescriptions prescribed and dispensed in primary care 
during the study period. GMS provided data on all other 
prescription medications dispensed to these patients, while 
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The authors emphasise that further research is needed to 
profile patients suitable for unsupervised dosing, with the 
aim of retention in treatment and reduced diversion. The 
authors caution that the study methodology did not capture 
patients transferring from primary care to specialised 
settings, may have underestimated retention, and did not 
consider the quality of treatment.
Cathy Kelleher
1 Cousins G, Boland F, Barry J, Lyons S, Keenan E, O’Driscoll D, 
Bennett K and Fahy T (2017) J-shaped relationship between 
supervised methadone consumption and retention in 
methadone maintenance treatment (MMT) in primary care: 
national cohort study. Drug and Alcohol Dependence, 173:  
126—131. http://www.drugsandalcohol.ie/26891/
2  Irish College of General Practitioners (2003) Working with opiate 
users in community based primary care. Dublin: Irish College of 
General Practitioners. http://www.drugsandalcohol.ie/5450/ 
3  Health Service Executive (2016) Clinical guidelines for opioid 
substitution treatment. Dublin: Health Service Executive. Available 
online at http://www.drugsandalcohol.ie/26573/
unsupervised failed to account for the relapsing nature of 
opioid addiction and the recurrence of treatment episodes. 
Consistent with research from Canada, many patients in the 
current study experienced multiple treatment episodes and 
were retained longer in later treatment episodes. Findings 
from a Scottish cohort study also suggest that cumulative 
exposure to opiate substitution improves patient survival. 
Although one-third of patients in the current study did not 
receive the recommended dosage, this proportion is lower 
than in the UK (57%) and Canada (51%). A further key finding 
is that many patients have comorbid conditions, and these 
patients tend to have shorter treatment episodes. 
Conclusion
The findings highlight a challenge for clinicians: reducing 
supervision risks increasing the availability of street 
methadone and hence the population level risk of 
methadone deaths, while increasing supervision risks 
dropout from treatment and greater patient mortality. 
Retention in treatment continued
• One-to-one qualitative semi-structured interviews were 
conducted with 10 patients, which were carried out in a 
neutral setting.
• Clinicians and patients were given a participant information 
sheet about the research, a draft of the intervention 
manual, and all relevant draft materials. 
–   The intervention manual contained a description of the 
main elements of the ASSIST screening tool and brief 
interventions. 
–   Draft material included a step-by-step guide for use by 
the clinician during the BI. Patient materials included 
items such as example pros and cons for changing 
substance use behaviour and take-home materials. 
• The main points of the focus groups and interviews were 
summarised and presented at the end of each session. 
Participants were asked to confirm whether it accurately 
reflected what had been discussed.
• Thematic analysis was chosen for data analysis. Themes 
were not determined in advance but emerged as patterns 
in the data and were grouped into themes. Themes were 
reviewed and refined.
Results
Feedback from clinicians and patients was used to guide the 
development of the BI and associated materials. Suggested 
changes were implemented if there was majority agreement, if 
in line with the key elements of BIs, and if practical.
• WHO uses two manuals to describe the ASSIST and a BI; 
these were combined into a single BI manual and the style 
of the manual refined. 
• A sample script of a screening and BI session was 
developed as well as an algorithm to facilitate clinicians 
during the BI session.
• A Substance Risk Card had been created for each 
individual substance assessed within the ASSIST screening 
tool. These cards outlined risks associated with the use of 
certain substances. 
Brief intervention 
with methadone 
patients
The use of a brief intervention (BI) has been recommended 
by the World Health Organization (WHO) as an intervention 
to address problematic substance use.1 It recommends a 
two-step approach, whereby the most problematic substance 
is first identified using the Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST). Once identified, the 
clinician can deliver a BI tailored for the identified substance. 
WHO advises refining and tailoring the BI to meet the needs of 
the target population, to consider the context and culture of 
the service setting, thus ensuring it meets local needs and is 
both culturally and contextually suitable.2
This paper outlines the development and process used to 
customise a BI for use with opioid-dependent methadone-
maintained patients and to ensure its compatibility with the 
culture of an Irish drug-using population.3 The authors sought 
to tailor all intervention materials for use in a subsequent 
cluster randomised controlled trial. 
Method 
Clinicians and patients took part in the process, which occurred 
in Dublin between December 2012 and February 2013.  
• Fifteen clinicians participated in two focus group sessions, 
which were conducted in two large addiction treatment 
centres in Dublin.
• Patient participants were opioid-dependent methadone-
maintained polydrug users not attending any of the study 
sites. They were recruited through a forum representing 
service users of addiction services. 
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The authors adhered to WHO recommendations to tailor BI 
programmes to be culturally and contextually appropriate to 
the treatment cohort and clinical environment. Qualitative 
methods were used to identify and implement modifications 
to the BI and material for use in a later trial. The BI manual 
was used to standardise training of clinicians for the later trial. 
Outcome data published elsewhere demonstrated that the 
tailored intervention was effective.4
Ita Condron
1 Humeniuk R, Henry-Edwards S, Ali R, Poznyak V and Monteiro 
MG (2010) Brief intervention: the ASSIST-linked brief 
intervention for hazardous and harmful substance use: manual 
for use in primary care. Geneva: World Health Organization. 
http://www.drugsandalcohol.ie/18939/ 
2  Humeniuk R, Dennington V and Ali R (2008) The effectiveness of a 
brief intervention for illicit drugs linked to the alcohol, smoking and 
substance involvement screening test (ASSIST) in primary health 
care settings: a technical report of phase III findings of the WHO 
ASSIST randomized controlled trial. Geneva: Department of Mental 
Health and Substance Dependence, World Health Organization. 
Available online at http://www.drugsandalcohol.ie/28120/
3 Darker CD, Sweeney B, Keenan E, Whiston L, Anderson R, Barry J 
(2016) Tailoring a brief intervention for illicit drug use and alcohol 
use in Irish methadone maintained opiate dependent patients: a 
qualitative process. BMC Psychiatry, 16(1): 373. 
4 Darker CD, Sweeney B, Keenan E, Whiston L, Anderson R, Barry 
J (2016) Screening and brief interventions for illicit drug use and 
alcohol use in methadone maintained opiate-dependent patients: 
results of a pilot cluster randomized controlled trial feasibility 
study. Subst Use Misuse, 51(9): 1104—15.
• The cards were modified: changes included weighting the 
severity of the risks, reordering associated risks with the 
more problematic risks at the top and the inclusion of how 
particular substances might interact with methadone and 
exacerbate problems for users. 
• Tickboxes were added to the risk cards. These boxes allow 
risks that are pertinent to a patient to be ticked by the 
clinician during a session, therefore tailoring the BI to the 
patient based on their own individual risk profile. 
• To address literacy concerns for illiterate or semi-literate 
patients, photographs were added to illustrate key  
risk factors.
• The language on the card was simplified and written in the 
first person to personalise the feedback.
• Patients recognised the physical risks of taking drugs, such 
as dental damage and the physical damage that long-term 
drug use can have on appearance.
• The ‘Pros and Cons of Substance Use’ section of a BI was 
used by the clinician to help patients explore why they use 
a substance and to consider reasons to reduce use or quit. 
Issues such as addiction, financial reasons to quit or cut 
down, risk of criminal activity and court conviction were 
important to patients and included as categories. More 
detail was added to examples.
• The value of proposed patient take-home material from 
the BI session, comprising the Feedback Report Card with 
results from the ASSIST screening tool and a personalised 
Substance Risk Card, was discussed. Patient opinion 
was divided on its usefulness. Concerns for patient 
confidentiality led to the adoption of a generic folder with 
a neutral title and cover. 
Brief intervention continued
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UPDATES
Recent 
publications
The following abstracts are cited  
from published journal articles recently 
added to the repository  
of the HRB National Drugs Library  
at www.drugsandalcohol.ie 
POLICY AND LEGISLATION
The emergence of the affected adult 
family member in drug policy discourse: 
a Foucauldian perspective 
Devaney E (2017) Drugs: Education 
Prevention and Policy, 24(4): 359—367. 
http://www.drugsandalcohol.ie/27534/
The affected adult family member has 
increasingly received attention in drug 
research, policy and practice fields; 
however, this development has received 
limited critical and theoretical examination 
with respect to the presuppositions 
underpinning its rationale.
The findings may be used as a starting point 
for critical reflection on the assumptions 
and privileged forms of knowledge and 
expertise that are shaping policy and 
practices relating to affected families. 
Irish General Practitioner (GP) 
perspectives toward decriminalisation, 
legalisation and cannabis for Therapeutic 
Purposes (CTP) 
Van Hout MC, Collins C, Delargy I  
and Crowley D (2017) International  
Journal of Mental Health and Addiction, 
15(5): 670—683.  
http://www.drugsandalcohol.ie/27072/  
The study aimed to investigate Irish  
general practitioner (GP) attitudes  
toward decriminalisation of cannabis and 
assess levels of support for therapeutic 
purposes (CTP). 
The study reflects concerns around the 
mental health consequences of cannabis 
use and potential for misuse in the event 
of legalisation, and the need for product 
regulation and an enhanced evidence 
base to support treatment decision 
making. Further research and medical 
education is warranted.
SERVICES
An exploratory service-based study of 
deliberate self-harm (DSH) in Ireland: ‘A 
hidden population’?
Quinn P, Surgenor P and McGilloway S 
(2017) Irish Medical Journal, 110(5): 561. 
http://www.drugsandalcohol.ie/27340/ 
The aim of this study was to investigate 
the nature and extent of deliberate 
self-harm (DSH) amongst those attending 
national crisis centres in Ireland, and to 
assess clients’ views of the service. A 
secondary analysis was undertaken of a 
large data set of clients presenting with 
DSH (n=823).
This is the first study in Ireland to provide 
insights into a ‘hidden population’ of 
people who engage in DSH. A need for 
greater awareness of DSH and its links to 
suicidal ideation/behaviour is indicated. 
Outcomes from a large 10 year hepatitis 
C treatment programme in people who 
inject drugs: no effect of recent or 
former injecting drug use on treatment 
adherence or therapeutic response  
Elsherif O, Bannan C, Keating S, 
McKiernan S, Bergin C and Norris S (2017) 
PLOS ONE, 12(6): e0178398.  
http://www.drugsandalcohol.ie/27486/
We evaluated for differences in 
treatment adherence and response to 
Peginterferon-alfa-2a/Ribavirin (Peg-
IFNα/RBV) in a large urban cohort with 
and without a history of remote or recent 
injection drug use.
Conclusions: PWID have comparable 
treatment adherence and SVR rates 
when compared to non-drug users 
treated with Peg-IFNα/RBV. These data 
support a public health strategy of HCV 
treatment and eradication in PWID in the 
DAA era.
Exploring patient characteristics and 
barriers to hepatitis C treatment 
in patients on opioid substitution 
treatment attending a community based 
fibro-scanning clinic 
Crowley D, Cullen W, Laird E, Lambert JS, 
McHugh T, Murphy C and Van Hout MC 
(2017) Journal of Translational Internal 
Medicine, 5(2): 112—119.
http://www.drugsandalcohol.ie/27666/
Hepatitis C virus (HCV) infection is 
a major public health issue. There is 
substandard uptake in HCV assessment 
and treatment among people who inject 
drugs (PWID). Community fibroscanning 
is used to assess disease severity and 
target treatment.
Conclusions: The study highlights the 
usefulness of community fibroscanning. 
Identifying barriers to treatment in this 
cohort affords an opportunity to increase 
the treatment uptake. The availability of 
afternoon clinics and enhanced prison 
linkage are warranted.
Community pharmacist experiences 
of providing needle and syringe 
programmes in Ireland 
McVeigh J, Hearne E, Bates G and  
Van Hout MC (2017) Research in Social 
Administration and Pharmacy,  
13(4): 767—777.
http://www.drugsandalcohol.ie/27519/ 
The aim was to understand and illustrate 
pharmacist experiences of providing 
needle and syringe programmes (NSP). 
Conclusions: Further enhancement of 
NSP coverage and targeted service 
delivery within national care pathways 
for drug and alcohol services is 
warranted. 
National Drugs Library
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Enhancing alcohol screening and brief 
intervention among people receiving 
opioid agonist treatment: qualitative study 
in primary care
McCombe G, Henihan AM, Klimas J,  
et al. (2016) Drugs and Alcohol Today,  
16(4): 247—258.
http://www.drugsandalcohol.ie/26946/ 
The purpose of this paper is to describe 
a qualitative feasibility assessment 
of a primary care-based complex 
intervention to promote screening and 
brief intervention for PAU, which also aims 
to examine acceptability and potential 
effectiveness.
Although a complex intervention to 
enhance alcohol screening and brief 
intervention among primary care patients 
attending for OAT is likely to be feasible and 
acceptable, time constraints and patients’ 
reticence to discuss alcohol as well as GPs 
underestimating patients’ alcohol problems 
is a barrier to consistent, regular and 
accurate screening by GPs.
Effectiveness of a national ‘Minnesota 
Model’ based residential treatment 
programme for alcohol dependence  
in Ireland: outcomes and predictors  
of outcome
Gallagher C, Radmall Z, O’Gara C  
and Burke T (2017) Irish Journal of 
Psychological Medicine, Early online
http://www.drugsandalcohol.ie/27545/ 
The aims of this study were (a) to examine 
the effectiveness of an inpatient treatment 
programme for alcohol dependence 
based on the ‘Minnesota Model’ and (b) to 
examine potential predictors of outcomes 
from such treatment.
This study provides evidence of the 
potential for a Minnesota-based treatment 
programme to be effective in helping 
people with alcohol dependence to reduce 
the amount of alcohol they consume 
and sustain this reduction beyond the 
treatment period.
Media coverage of alcohol issues: a critical 
political economy framework — a case 
study from Ireland
Mercille J (2017) International Journal of 
Environmental Research and Public Health, 
14(6): 1—13.
http://www.drugsandalcohol.ie/27433/ 
This paper presents such a framework 
that conceives of news organisations as 
corporations that share the values and 
interests of political and economic elites.
Results show that, overall, 44.0% of 
articles support public health measures 
and 56.0% are opposed or remain neutral.
A systematic review of the relationship 
between staff perceptions of 
organizational readiness to change and 
the process of innovation adoption in 
substance misuse treatment programs
Kelly P, Hegarty J, Barry J, Dyer KR and 
Horgan A (2017) Journal of Substance Abuse 
Treatment, 80: 6—25.
http://www.drugsandalcohol.ie/27435/ 
The aim of this review was to describe the 
relationship between staff perceptions of 
organizational readiness to change (ORC) 
and the process of innovation adoption: 
exposure, adoption, implementation 
and integration into practice, in 
substance misuse treatment programs. 
This systematic review was conducted 
in accordance with PRISMA guidelines 
and fourteen papers were identified as 
being eligible for inclusion. This review 
was designed to include all constructs 
of ORC, but only one tool was used in all 
of the included papers. Despite this, the 
heterogeneity of studies in this review 
made a direct comparison of ORC related 
variables challenging.
Supportive text messages for patients 
with alcohol use disorder and a comorbid 
depression: a protocol for a single-blind 
randomised controlled aftercare trial
Hartnett D, Murphy E, Kehoe E, Agyapong 
V, McLoughlin DM and Farren C (2017)  
BMJ Open, 7(5): e013587.
http://www.drugsandalcohol.ie/27406/ 
Alcohol use disorders (AUDs) and mood 
disorders commonly co-occur, and are 
associated with a range of negative 
outcomes for patients. Mobile phone 
technology has the potential to provide 
personalised support for such patients 
and potentially improve outcomes in this 
difficult-to-treat cohort. The aim of this 
study is to examine whether receiving 
supporting SMS text messages, following 
discharge from an inpatient dual diagnosis 
treatment programme, has a positive 
impact on mood and alcohol abstinence 
in patients with an AUD and a comorbid 
mood disorder.
The trial has received full ethical approval.
PREVALENCE AND CURRENT 
SITUATION
The involvement of alcohol in hospital-
treated self-harm and associated factors: 
findings from two national registries
Griffin E, Arensman E, Perry IJ, Bonner B, 
O’Hagan D, Daly C and Corcoran P (2017) 
Journal of Public Health, Early online
http://www.drugsandalcohol.ie/27314/ 
Alcohol is often involved in hospital-
treated self-harm. Therefore it is 
important to establish the role of alcohol  
in self-harm as well as to identify 
associated factors, in order to best  
inform service provision.
Conclusions: This study has highlighted 
the prevalence of alcohol in self-harm 
presentations, and has identified factors 
associated with presentations involving 
alcohol. Appropriate out-of-hours services 
in emergency departments for self-harm 
presentations could reduce the proportion 
of presentations leaving without being 
seen by a clinician and facilitate improved 
outcomes for patients.
Daily and occasional smoking and quitting 
in Irish university students
McKee G, Barry J, Mullin M, Allwright S and 
Hayes C (2017) Health, 9: 435—450.
http://www.drugsandalcohol.ie/27184/
This study assessed prevalence of student 
smoking and quitting behaviors and 
associated demographic, contextual and 
attitudinal factors.
Intentions to quit smoking and quit 
attempts were high among all smokers 
although use of on-site cessation supports 
was less than the optimal. These combined 
factors indicate a need for better targeting 
of our prevention strategies and the need 
to promote greater awareness of cessation 
supports for successful implementation of 
a smoke-free campus.
Non-medical use of olanzapine by people 
on methadone treatment
James PD, Fida AS, Konovalov P and Smyth 
BP (2016) BJPsych Bulletin, 40(6): 314—317.
http://www.drugsandalcohol.ie/27140/ 
We examined non-medical use (NMU) of 
olanzapine among adults on methadone 
treatment. A small minority show features 
of dependency. All doctors should be 
aware of the potential NMU of olanzapine, 
especially among patients with history of 
addiction.
The dynamic landscape of novel 
psychoactive substance (NPS) use 
in Ireland: results from an expert 
consultation
Van Hout MC (2016) International  
Journal of Mental Health and Addiction, 
15(5): 985—992.
http://www.drugsandalcohol.ie/27073/ 
The study aimed to investigate expert 
perspectives on the NPS situation with 
regard to changing and emergent trends in 
use, health and social consequences and 
service implications.
Findings underscored the mental health 
and addiction related consequences of 
NPS use, with prevention, clinical and 
treatment services ill-equipped to deal 
with the particular characteristics of this 
form of drug abuse. 
Recent publications continued
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Enhanced strategies, services and clinical 
responses are warranted to address the 
challenges encountered.
Shake ‘N Bake: the migration of ‘pervitin’ 
to Ireland
Van Hout MC and Hearne E (2016) 
International Journal of Mental Health  
and Addiction, 15(4): 919—927.
http://www.drugsandalcohol.ie/27074/ 
We present the first single case study 
of clandestine production of ‘Pervitin’ 
to Ireland, a country with low reporting 
history of methamphetamine.
The study yielded unique insight into 
migration of this culturally specific drug, 
and how continued cultural contexts for 
use and ‘cooking’ remain intact when 
residing in the host country. Given its 
unique cultural nature and national 
characteristics, continued migration of 
Eastern European citizens across Europe, 
diffusion of clandestine production 
warrants continued surveillance. 
Appropriate service responses require 
culturally appropriate information and 
outreach services to Eastern European 
service users.
Out of sight, out of mind? A national 
survey of paediatricians in Ireland 
regarding Fetal Alcohol Spectrum 
Disorders
Gill I and Sharif F (2017)  
Irish Medical Journal, 110(3): 528.
http://www.drugsandalcohol.ie/27024/
We aimed to evaluate self-reported 
knowledge and practice of doctors working 
in paediatrics in Ireland with regards to 
FASDs and alcohol consumption during 
pregnancy. Our survey suggests prenatal 
alcohol exposure may not be routinely 
considered in the evaluation of children 
with developmental delay by paediatric 
doctors in Ireland.
Opiate addiction and overdose: 
experiences, attitudes, and appetite for 
community naloxone provision
Barry T, Klimas J, Tobin H, Egan M and 
Bury G (2017) British Journal of General 
Practice, 67(657): e267—e273.
http://www.drugsandalcohol.ie/26952/
The study aimed to establish GPs’ views 
and experiences of opiate addiction, 
overdose care, and naloxone provision.
Conclusions: GPs report extensive contact 
with people who have opiate use disorders 
but provide limited opiate agonist 
treatment. They support wider availability 
of naloxone and would participate in its 
expansion. Development and evaluation of 
an implementation strategy to support GP-
based distribution is urgently needed.
The challenge of complex drug use: 
Associated use of codeine-containing 
medicines and new psychoactive 
substances in a European cross-sectional 
online population
Kimergård A, Foley M, Davey Z, Wadsworth 
E, Drummond C and Deluca P (2017) Human 
Psychopharmacology, 32(3): e2611.
http://www.drugsandalcohol.ie/27423/ 
This study characterises codeine 
consumption amongst NPS users and  
non-NPS users to provide warning of  
health issues.
Conclusions: Amongst NPS users, codeine 
is less likely to be used daily but more 
likely to be used for recreational purposes. 
Smaller populations engaging  
in high-risk use exist who take multiple 
drugs in high doses. Combinations of 
misused codeine and NPS highlight the 
need for policy to respond to a more 
complex drug situation.
Health student regard for substance-using 
patients as measured by the  
Medical Condition Regard Scale:  
a systematic review
Ducray K and Pilch M (2017) Irish Journal of 
Psychological Medicine, 34: 183—196. 
http://www.drugsandalcohol.ie/27344/
The purpose of this review was to identify 
trends and patterns in health student, 
namely future practitioners’, regard for 
substance-using patients using the Medical 
Condition Regard Scale. 
This review found that patients with drug-
use problems were consistently held in the 
lowest echelons of regard by trainee health 
practitioners. The impact of sex, age, year 
of course, and personal exposure to mental 
health difficulties in predicting negative 
regard was unclear.
Unless addressed, patients with drug 
problems may have a high potential for 
future treatment marginalisation by 
tomorrow’s health professionals. This 
scenario needs to be proactively managed 
by all stakeholders through a greater 
investment in educational and clinical 
training placement opportunities.
Exploring Irish Travellers’ experiences 
of opioid agonist treatment: a 
phenomenological study
Claffey C, Crowley D, MacLachan M and 
Van Hout MC (2017) Heroin Addiction and 
Related Clinical Problems, Early online 
http://www.drugsandalcohol.ie/27566/ 
The study aimed to explore and describe 
Irish Travellers’ experiences of drug use 
and opioid agonist treatment (OAT), with 
a view to improving service delivery and 
expanding the limited research base.
Conclusions: The development of 
culturally appropriate, gender sensitive 
and integrated OAT and mental health 
support services, designed with input from 
addiction and mental health specialists, 
alongside community members is 
warranted.
A national audit of smoking cessation 
services in Irish maternity units
Reynolds CME, Egan B, Cawley S, Kennedy 
R, Sheehan SR and Turner MJ (2017) Irish 
Medical Journal, 110(6): 580.
http://www.drugsandalcohol.ie/27564/
There is international consensus that 
smoking cessation in the first half of 
pregnancy improves foetal outcomes.  
We surveyed all 19 maternity units 
nationally about their antenatal smoking 
cessation practices.
Although smoking is an important 
modifiable risk factor for adverse 
pregnancy outcomes, smoking cessation 
services are inadequate in the Irish 
maternity services and there are variations 
in practices between hospitals.
Exploring smoking, mental health and 
smoking-related disease in a nationally 
representative sample of older adults 
in Ireland – A retrospective secondary 
analysis
Burns A, Strawbridge J, Clancy L and 
Doyle F (2017) Journal of Psychosomatic 
Research, 98: 78—86.
http://www.drugsandalcohol.ie/27274/
Smoking is the leading preventable cause 
of death among individuals with mental 
health difficulties (MHD). The aim of the 
current study was to determine the impact 
of smoking on the physical health of older 
adults with MHD in Ireland and to explore 
the extent to which smoking mediated or 
moderated associations between MHD and 
smoking-related diseases.
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17 The paradox of public holidays: 
hospital-treated self-harm and 
associated factors 
Griffin E, Dillon CB, O’Regan G,  
Corcoran P, Perry IJ and Arensman E 
(2017) Journal of Affective Disorders,  
218: 30—34.
http://www.drugsandalcohol.ie/27285/ 
This study used national data to examine 
the patterns of hospital-treated self-
harm during public holidays, and to 
examine associated factors.
Conclusions: Public holidays are 
associated with an elevated number 
of self-harm presentations to hospital, 
with presentations to hospital involving 
alcohol significantly increased on these 
days. Hospital resources should be 
targeted to address increases during 
public holidays, including during out-of-
hours. Involvement of alcohol may delay 
delivery of care to these patients in 
emergency settings.
Suicide among young people and adults 
in Ireland: method characteristics, 
toxicological analysis and substance 
abuse histories compared
Arensman E, Bennardi M, Larkin C,  
Wall A, McAuliffe C, McCarthy J, 
Williamson E and Perry IJ (2016)  
PLOS ONE, 11(11): e0166881.
http://www.drugsandalcohol.ie/27275/ 
The aim of this study was to identify 
socio-demographic characteristics  
and circumstances of death associated 
with age among individuals who died  
by suicide.
Conclusions: Based on this research 
it is recommended that strategies to 
reduce substance abuse be applied 
among 25—34-year-old individuals at 
risk of suicide. The wide use of hanging 
in young people should be taken 
into consideration for future means 
restriction strategies.
Anxiety and depression among patients 
with alcohol dependence: co-morbid or 
substance-related problems? 
Gallagher C, Radmall Z, O’Gara C 
and Burke T (2017) Irish Journal of 
Psychological Medicine, Early online
http://www.drugsandalcohol.ie/27544/ 
The aim of this study was to characterise 
rates of co-morbid psychiatric 
symptoms among a group of individuals 
commencing treatment for alcohol 
dependence, and to examine the 
stability of these symptoms following 
treatment of the alcohol problem.
The significant change in rates 
of reported symptoms following 
completion of treatment suggests 
that a large proportion of symptoms 
reported at treatment entry were 
substance related. Diagnosing co-
morbid conditions is best left until after 
a period of abstinence during which the 
alcohol problem has been treated.
Home manufacture of drugs: an online 
investigation and a toxicological reality 
check of online discussions on drug 
chemistry 
Hearne E, Alves EA, Van Hout MC 
and Grund JPC (2017) Journal of 
Psychoactive Drugs, 49(4): 279—288.
http://www.drugsandalcohol.ie/27580/
We illustrate here how online communal 
folk pharmacology of homemade drugs 
on drug website forums may actually 
inform home manufacture practices 
or contribute to the reduction of 
harms associated with this practice. 
Discrepancies between online 
information around purification and 
making homemade drugs safer, and the 
synthesis of the same substances in a 
proper laboratory environment, exist.
Drug discussion forums should consider 
reevaluating their policies on chemistry 
discussions in aiming to reach people 
who cannot or will not refrain from 
cooking their own drugs with credible 
information that may contribute to 
reductions in the harms associated with 
this practice.
An investigation into the effect of 
alcohol consumption on health status 
and health care utilization in Ireland 
Ormond G and Murphy R (2017)  
Alcohol, 59: 53—67.
http://www.drugsandalcohol.ie/27149/ 
This paper presents a study of the 
effect of alcohol consumption on 
individual health status and health care 
utilization in Ireland using the 2007 Slán 
National Health and Lifestyle Survey, 
while accounting for the endogenous 
relationship between alcohol and health.
Findings show that in Ireland, moderate 
drinkers enjoy the best health status. 
More moderate drinkers report having 
very good or excellent health compared 
with heavy drinkers, non-drinkers, or 
those who never drank. While heavy 
drinkers do not report having as good a 
health status as moderate drinkers, they 
are better off in terms of health when 
compared with non-drinkers and those 
who are lifetime abstainers.
Codeine use, dependence and help-
seeking behaviour in the UK and Ireland: 
an online cross-sectional survey 
Kimergård A, Foley M, Davey Z, Dunne J, 
Drummond C and Deluca P (2017)  
QJM, 110(9): 559—564.
http://www.drugsandalcohol.ie/27129/
Codeine misuse and dependence 
poses a clinical and public health 
challenge. However, little is known about 
dependence and treatment needs in the 
UK and Ireland.
Conclusions: Codeine dependent users 
were more likely to seek help on the 
Internet to control their use of codeine 
than from a GP, which may indicate 
a potential for greater specialised 
addiction treatment demand through 
increased identification and referrals in 
primary care.
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